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The central nervous system controls many physiological processes including 
energy metabolism, immune response, reproduction, and development. In turn, hormones 
synthesized in and secreted by peripheral organs can be transported across the blood-
brain barrier to modulate the development of the brain, the formation of new neurons, 
neural activity, behavior, and the secretion of brain-derived hormones. The central 
control of bone mass, mediated by the adipocyte-derived hormone leptin, has raised 
questions of whether the skeleton may signal back to the brain.  
In recent years, the Karsenty laboratory has uncovered the endocrine role of the 
bone-derived hormone osteocalcin. Through the use of a vast array of genetic tools, the 
Karsenty lab has discovered that osteocalcin is a potent regulator of glucose homeostasis, 
adaptation to exercise, energy metabolism, and male fertility. The multifunctional role of 
osteocalcin led us to hypothesize that it may act as a molecular means of communication 
between the skeleton and the brain. We asked whether osteocalcin could regulate brain 
development during embryogenesis and behavioral functions in adulthood. In addressing 
these questions, we observed that bone-derived osteocalcin crosses the blood-brain 
barrier, accumulates in discrete parts of the brain including the hippocampus, and binds 
to several neuronal populations to favor the synthesis of monoamine neurotransmitters 
(serotonin, dopamine, and norepinephrine), and to impede the synthesis of the inhibitory 
neurotransmitter, GABA. Osteocalcin-/- mice have increased anxiety and depression and 
impaired learning and memory when compared to WT littermates. We also uncovered 
that the absence of maternal osteocalcin during embryogenesis hinders brain development 
and causes defects in spatial learning and memory in the adult offspring. 
Upon characterizing the necessity of osteocalcin for brain development and 
cognitive function, we investigated whether bone health is a determinant of cognition, 
and whether osteocalcin may be sufficient to reverse age-related cognitive decline. In 
addressing the first question, we found that impairment in either bone formation or bone 
resorption negatively impacts both anxiety and memory. In addressing the second 
question, we found that osteocalcin is also necessary for the beneficial effect of young 
blood on cognitive functions. Finally, we observed reduced anxiety and improved 
memory in aged mice receiving osteocalcin peripherally. This action appears to require 
an increase in brain-derived neurotrophic factor levels in the hippocampus.  
Against the backdrop of our progressively aging population, it is important for 
future studies to determine whether osteocalcin may act therapeutically in humans to treat 
age-related cognitive decline. Additionally, to identify potential drug targets, it is 
important to fully characterize the molecular mechanism by which osteocalcin acts on 
neurons.  
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Chapter 1. Introduction 
	  
Bone’s Contribution to Whole Organism Physiology 
	  
An Introduction to the Skeleton 
When we think of the skeleton, we think of a large, stable, almost inert structure 
on which we rely to stand, walk, and if necessary, run. Yet, perhaps not surprisingly, 
bone is a highly dynamic organ that renews itself from birth to death. Bone turnover is 
necessary to maintain the functions of the skeleton throughout the life of the organism; in 
other words, to maintain life.  
There are two major cell types in the bone. The first cell type is the osteoblast, 
which is a cuboidal, mononucleated cell, derived from mesenchymal stem cells (MSCs) 
in the bone marrow. MSCs can also differentiate into chondrocytes, adipocytes (fat cells), 
and myocytes (muscle cell precursors). Multiple studies performed in the last 20 years 
have shown that it takes several steps, including committed osteoprogenitor and 
preosteoblast, for an MSC to become a fully differentiated osteoblast (Karsenty, 2013).  
Understanding the many functions of differentiated osteoblasts is important for 
this work. First and foremost, the mature osteoblasts, which are embedded in the bone 
matrix, are responsible for bone formation; i.e., synthesis of Type I collagen, which 
comprises 90% of bone, and is the main structural protein of the bone matrix. Osteoblasts 
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are also responsible for the production of many non-collagenous proteins, including the 
most abundant one, osteocalcin (Ducy et al., 2000b).  
Second, osteoblasts facilitate the mineralization of the bone extracellular matrix, 
which is essential for the strength and hardness of the skeleton. Osteoblasts express genes 
such as PHEX (phosphate-regulating neutral endopeptidase) and alkaline phosphatase 
that can initiate the formation of hydroxyapatite crystals containing calcium and 
inorganic phosphate ions, which they deposit on collagen fibrils to form the actual bone 
trabeculae (Murshed et al., 2005). The third important function of osteoblasts is the 
differentiation of the second cell type in the bone, the osteoclast, which is responsible for 
bone resorption. Osteoblasts express two cytokines essential for osteoclastogenesis, 
macrophage colony-stimulating factor (M-CSF) and receptor activator of nuclear factor-
KappaB ligand (RANKL), while osteoclasts express the receptors of these 
cytokines. Osteoblasts also produce osteoprotegerin (OPG), a decoy receptor for 
RANKL, which inhibits the interaction between RANKL and RANK, a receptor of 
RANKL, and thereby inhibits osteoclast differentiation. Wnt proteins activate two 
pathways: beta-catenin-dependent canonical and beta-catenin-independent noncanonical 
pathways. In osteoblasts, the canonical pathway in osteoblasts suppresses 
osteoclastogenesis through the up-regulation of Opg expression and the down-regulation 
of RANKL expression. In contrast, activation of the noncanonical pathway 
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in osteoclast precursors enhances RANKL-induced osteoclast differentiation (Takahashi 
et al., 2011).  
A recent development of bone biology has been the finding that the osteoblast is 
responsible for the endocrine functions of bone by producing the hormones FGF23, 
lipocalin-2, and osteocalcin, described below.  
 
Bone Remodeling and Osteocalcin 
 
 Together, osteoblasts and osteoclasts are responsible for bone modeling and 
remodeling. In humans, from the start of embryogenesis through approximately the first 
20 years of life, the skeleton undergoes bone modeling, which determines its shape and 
height. It is the process responsible for skeletal growth and for establishing the final 
structure of the organism. In the absence of bone modeling, a vertebrate animal is unable 
either to grow or to walk; ultimately, it withers. Hence, by definition, bone modeling is a 
survival function. On the other hand, bone remodeling is a lifelong process that starts 
after the end of longitudinal growth. It involves a perpetual alternation of bone resorption 
followed by bone formation in basic multicellular units (BMU)s. Each BMU consists of a 
group of cells that remodels on its own clock. In general, within each BMU, any bone 
that is resorbed must be replaced with an equal amount of new bone. During growth, the 
rate of bone formation is more rapid than resorption, while the opposite is true during 
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aging. This is exacerbated in female animals, concurrent with menopause, which explains 
the development of post-menopausal osteoporosis.  Bone remodeling is necessary to 
maintain calcium homeostasis, repair any damage; i.e., fractures, and remove old bone. It 
takes approximately 10 years for the human skeleton to get replaced through bone 
remodeling (Karsenty, 2013).  
 As previously mentioned, osteoblasts also synthesize and secrete non-collagenous 
proteins, the most abundant of which is osteocalcin.  In mice, osteocalcin is a 46-amino 
acid peptide (49-amino acid in humans) containing a hydrophobic region at the C-
terminus, three helical domains, and an N-terminus that is not structured (Gundberg et al., 
2012). Osteocalcin has 3 glutamic acid residues (Glu) that γ-carboxylase, an enzyme 
which is present in the osteoblast and whose activity is dependent on vitamin K levels, 
carboxylates to form carboxyglutamic acid residues (Gla). These residues confer to 
osteocalcin a high affinity for mineral crystal and mineral ions, resulting in the 
longstanding belief that osteocalcin should be necessary for bone mineralization. 
However, mice lacking osteocalcin mineralize their bone normally. Instead, the 
undercarboxylated form of osteocalcin is able to carry out bone’s endocrine functions 
described below (Lacombe and Ferron, 2015). Low pH is the only known mechanism by 
which decarboxylation occurs. When osteoclasts are activated, they create resorption 
lacunae with a pH of 4.5 that simultaneously results in osteocalcin decarboxylation 
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(Figure 1). Accordingly, in mice and in humans, when bone resorption is impaired, 
bioactive circulating levels of osteocalcin are decreased (Karsenty and Ferron, 2012). 
 
The Endocrine Functions of Bone 
 
 Currently, there are three known hormones secreted by bone. The first is FGF23, 
a member of the fibroblast growth factor family that is secreted by osteoblasts and 
osteocytes, and regulates vitamin D levels, and consequently phosphate and calcium 
metabolism (Liu et al., 2007; Quarles, 2012). In other words, FGF23 is an endocrine 
regulator of bone mineralization. The second hormone is called lipocalin 2, which was 
shown recently by the Kousteni lab in the Department of Physiology and Cellular 
Biophysics at CUMC to regulate appetite (Mosialou et al., in press). The third hormone, 
which is the topic of my graduate work, is osteocalcin. 
Initially, our laboratory began to study osteocalcin thinking, incorrectly as it later 
became evident, that this protein may be necessary to initiate bone mineralization since it 
is an osteoblast-specific molecule, and mineralization only takes place in the presence of 
osteoblasts. However, Osteocalcin null mice (Ocn-/-) had no defect in bone 
mineralization (Ducy et al., 1996). Moreover, the ectopic expression of osteocalcin in 
cartilage or arteries does not lead to mineralization of these tissues (Yagami et al., 1999). 
This suggested that osteocalcin must have another function. A thorough analysis of Ocn-
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/- mice showed time and again that these mice displayed an increase in abdominal fat, 
and that male Ocn-/- mice were poor breeders. These observations led the Karsenty lab to 
propose a hypothesis that osteocalcin, which is present in the general circulation, may be 
a hormone influencing physiological processes unrelated to bone mineralization 
(Karsenty and Olson, 2016). 
Consistent with this paradigm-shifting hypothesis in skeletal biology, an in depth 
analysis of the Ocn-/- mice revealed that they are hyperglycemic, hypoinsulinemic, and 
insulin resistant, and have a decrease in energy expenditure. A series of simple co-culture 
experiments confirmed the ability of osteocalcin to act directly on cells from different 
organs. For instance, supernatant from WT osteoblasts could stimulate Insulin expression 
and secretion in cultured pancreatic β cells, and Adiponectin expression and secretion in 
cultured adipocytes. However, the supernatant of Ocn-/- osteoblast cultures failed to 
retain this ability. These effects were specific to osteocalcin, since supernatant from other 
cell types could not stimulate insulin and adiponectin secretion, and these were the only 
molecules whose release was affected by osteocalcin in β cells and adipocytes, 
respectively (Ferron et al., 2008; Lee et al., 2007). Later it was found that in fasting adult 
humans, circulating osteocalcin levels are inversely correlated with body fat and body 
mass index, extending the role of osteocalcin in regulating energy metabolism to patients 
(Fernandez-Real et al., 2009). Subsequent studies found that mice deficient in Gprc6a, a 
G-protein-coupled receptor, phenocopied the metabolic defects of Ocn-/- mice (Pi et al., 
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2008). The cell-specific knockout of Gprc6a revealed that this receptor mediates 
osteocalcin signaling in pancreatic β cells, since mice lacking Gprc6a only in the β-cell 
lineage have defects in β cell proliferation, are glucose intolerant, and have an impaired 
ability to produce insulin (Wei et al., 2014). 
In addition to its role in regulating energy metabolism, osteocalcin also greatly 
influences male fertility. Similar co-culture experiments as described above revealed that 
supernatant from WT but not Ocn-/- osteoblasts could stimulate testosterone production 
by Leydig cells of the testis. Consequently, Ocn-/- male mice have low levels of 
circulating testosterone, low sperm count, and are poor breeders with small litter sizes 
and reduced testis, epididymis and seminal vesicle weight. Male mice lacking osteocalcin 
specifically in osteoblasts (Ocnosb−/−) had the same defects in testosterone production as 
Ocn-/- male mice, while the deletion of Ocn in Leydig cells did not affect male fertility 
(Oury et al., 2011). These finding established that bone regulates testosterone synthesis in 
the male gonad. Further investigation revealed that osteocalcin binds to its specific 
receptor, Gprc6a, on Leydig cells of the testes, which are responsible for testosterone 
production, to stimulate testosterone synthesis in a cAMP/CREB dependent pathway 
(Oury et al., 2011) (Figure 2). Of note, subsequent studies in patients with primary 
testicular failure revealed that mutations in Gprc6a were causative for this disease, 
expanding the endocrine role of osteocalcin in male fertility to humans (Oury et al., 
2013a).  
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More recently, two intriguing observations about osteocalcin biology led to a 
novel connection between bone and muscle.  First, it was found that circulating bioactive 
levels of osteocalcin more than doubled immediately after endurance exercise. Inversely, 
bioactive osteocalcin levels drop dramatically around midlife in mice, monkeys, and 
humans, regardless of gender. Since aging leads to a reduction in exercise capacity, these 
observations raised the question of whether osteocalcin can signal in myofibers, the cells 
which comprise striated muscle. Genetic studies revealed that during exercise, 
osteocalcin signaling in myofibers promotes the uptake of glucose and fatty acids into 
these cells, which is their main source of nutrition (Figure 4). Osteocalcin also stimulates 
the release of the myokine interleukin-6, which in turn favors the release of additional 
bioactive osteocalcin. Additionally, osteocalcin is sufficient to restore exercise capacity 
in older mice (Mera et al., 2016). 
 
The Central Control of Bone Mass 
Leptin, a peptide hormone, produced and secreted by adipocytes, controls satiety 
and energy metabolism. Interestingly, ob/ob or db/db mice, which are null for either 
leptin or its receptor, respectively, have smaller brains, and hypogonadism, but also high 
bone mass. The co-occurrence of high bone mass and hypogonadism implied de facto 
that leptin is a very powerful regulator of bone mass. Conversely, when leptin is 
delivered centrally (ICV) at a dose that does not cross the BBB, bone mass decreases in 
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ob/ob.  To uncover the underlying connection between leptin and bone mass, our 
laboratory showed that serotonergic signaling in the ventromedial nuclei in the 
hypothalamus (VMH) inhibits sympathetic nervous system (SNS) activity; the SNS 
normally inhibits bone resorption and favors bone formation, i.e., it increases bone mass.  
When adipocyte-derived leptin crosses the blood brain barrier and binds to its receptor, 
OBRb, expressed on serotonergic neurons in the brainstem, this inhibits serotonin 
synthesis, and SNS activity, in turn inhibiting bone formation and favoring bone 
resorption (Figure 3). Indeed, mice that lack the leptin receptor in serotonergic neurons of 
the brainstem phenocopy the high bone mass of ob/ob mice (Yadav and Karsenty, 2009; 
Yadav et al., 2009). Another mechanism by which leptin regulates bone mass is through 
hypothalamus-derived cocaine amphetamine regulated transcript (CART), a target gene 
of leptin signaling in the hypothalamus. Cart-/- mice have normal appetite, but increased 
bone resorption and consequently, low bone mass (Elefteriou et al., 2005). The fact that 
the brain is such a powerful regulator of bone mass raised the question of whether bone 
signals back to the brain. 
 
Evidence of the Bone-Brain Connection 
 
 My thesis work has focused on the influence of the skeleton on the brain. While a 
direct link between bone and skeletal physiology may be surprising, there are several 
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examples of neurologic diseases accompanied by anomalous bone including human 
diseases such as CNS damage due to stroke, spinal cord injury, etc. which can lead to 
osteoporosis (Jiang et al., 2006). In Major Depressive Disorder (MDD), in addition to the 
well-known symptoms of chronic sadness, feelings of worthlessness, and increased risk 
for suicide, several studies have shown both in pre- and post-menopausal women that 
clinical depression is correlated with low bone mass, low bone density, and low 
circulating levels of osteocalcin, a marker of bone formation (Altindag et al., 2007; Fava 
and Kendler, 2000).  
While those studies are correlative, an example of a genetic skeletal disease in 
which cognitive functions are also affected is cleidocranial dysplasia (CCD). CCD results 
from mutations in the gene Runx2. Runx2 is a member of the Runt family of transcription 
factors that the Karsenty laboratory identified is expressed in MSCs destined to become 
osteoblasts. Importantly for my research, Runx2 was originally identified as a 
transcription factor regulating the expression of Osteocalcin. Runx2 null mice have no 
bone and die shortly after birth (Ducy et al., 1997; Karsenty, 2008). However, 
happloinsufficiency of Runx2 in mice and in humans is not lethal, but results in CCD, 
which is characterized by severe skeletal abnormalities including small or missing 
clavicles, a delay in the closure of the fontanels, short stature, dental defects, and low 
bone mass (Cohen, 2013). Importantly for my studies, patients with CCD also exhibit 
cognitive impairments, which suggests that a defect in osteoblast development may 
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influence brain function (Izumi et al., 2006; Takenouchi et al., 2014). Since osteoblasts 
are responsible for the production of osteocalcin, this raises the question of whether 
decreased osteocalcin production could be the cause of these cognitive defects. These 
observations were an incentive to test this hypothesis in a mouse model of Runx2 
happloinsufficiency, which will be explored in the next chapter.  
 Of relevance also for the second study presented in Chapter 2, aging represents a 
multifaceted link between bone and brain biology. Age-related cognitive decline is 
growing in prevalence as our population ages. This disease can range anywhere from 
mild cognitive impairment and age-related memory loss to severe dementia and 
Alzheimer’s disease (Gazzaley and Small, 2011; Mayeux, 2010). As far as the skeleton is 
concerned, aging is characterized by a decrease in bone mass (Karsenty, 2006). In elderly 
populations, a decline in cognitive functions increases the risk of falling, as does the risk 
of fracture due to decreased bone density, resulting in a vicious cycle (Hsu et al., 2012). 
Moreover, many studies have now shown that bone loss itself can act as an early 
predictor of age-related memory loss, with elderly people in the lowest quartile of bone 
mass being twice as likely to develop a cognitive deficit (Lui et al., 2003). Although these 
studies are also correlative and need to be interpreted with caution, they suggest that a 
relationship may exist between bone and the brain. These studies are also important for 
my work in view of the recent finding that bioactive osteocalcin levels drop dramatically 
in aging mice, monkeys, and humans, regardless of gender (Mera et al., 2016).  
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To lay the groundwork in understanding the role of osteocalcin in regulating brain 
development and function, which has been the focus of my graduate studies, the next 
section will focus on a brief history about the neuronal basis of memory formation.  
 
Mechanisms of Cognition 
 
A Brief History 
 
 Our first clues that specific regions of the brain are responsible for distinct 
behaviors came in the mid-1800s from the works of neurologists Paul Broca and Carl 
Wernicke. Broca studied patients who were unable to verbalize, while Wernicke worked 
with those who could not understand speech. Autopsies performed by these physicians 
revealed that language is localized to specific regions in the left hemisphere. These 
regions were later coined Broca’s area for speech production and Wernicke’s area for 
language comprehension (Kandel, 2013). 
 A major advancement in neuroscience came from the remarkable work of 
Santiago Ramon y Cajal, who demonstrated that the brain is comprised of billions of 
discrete cells that communicate with each other. Using the revolutionary staining method 
developed by his contemporary, Camillo Golgi, Cajal was able to visualize entire 
individual neurons entangled with neighboring unstained cells. Cajal observed that 
postnatally, the number of neurons in an organism’s brain does not increase dramatically 
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as it continues to develop. This suggested that connections between pre-existing neurons 
are responsible for the formation and storage of memories, rather than the formation of 
new neurons. Experiments performed over the course of the following century and a half 
have supported Cajal’s conclusions (Kandel, 2001).  
 The next major focus of neurobiology became to address how individual neurons 
communicated with each other to form memories. Charles Sherrington named the point 
of contact between two nerve cells the synapse (Sherrington, 1973). A synapse generally 
consists of a presynaptic active zone containing synaptic vesicles, a synaptic cleft, and 
postsynaptic density (Holtmaat and Svoboda, 2009). Both the strengthening and 
weakening of existing synapses (functional synaptic plasticity), and the creation or 
elimination of synapses (structural plasticity) are lifelong processes. They give the brain 
its ability to adapt based on the individual’s experiences are major mechanisms by which 
memories are made, stored, or deleted (Kandel, 2001; Kandel, 2013). 
 In the mid-twentieth century, Donald Hebb put forth one mechanism of synaptic 
plasticity, later termed Hebb’s theory of associative learning (Hebb, 1949).  Hebb’s 
postulate states that when neuron A fires repeatedly upon neuron B, the connection 
between the two becomes stronger in that neuron A is able to fire more easily on neuron 
B. In this way, an associative memory is formed. Under this model, it is possible for an 
individual cell to be involved in more than one memory association, for example, in 
response to temporal or contextual changes. In the 1980s, Wigstrom and Gustaffson 
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combined Hebb’s theory with the work of others to describe long-term potentiation (LTP) 
as a major mechanism for associative learning (Wigstrom and Gustafsson, 1985). 
 Given that the phenomena of synaptic plasticity and LTP were present in neural 
connections throughout the brain, focus shifted to the identification of brain regions 
responsible for memory acquisition and storage. As had been the case in the identification 
of Broca’s and Wernicke’s areas as major language centers, the importance of the 
hippocampal structure for memory was discovered by lesion studies. The most famous of 
these is the case of Henry Molaison, known more commonly as patient H.M. (Scoville 
and Milner, 1957). To treat his persistent epilepsy, which involved scar formation in the 
hippocampus on both sides, H.M. underwent a surgery in which the hippocampus was 
completely removed from each hemisphere. The surgery was able to cure his epilepsy, 
but had a striking and profound side effect. It rendered H.M. incapable of forming any 
new explicit memories including facts, events, and spatial learning (Barco et al., 2006). 
For example, H.M. could not remember the names and faces of any new person he met. 
Interestingly, however, he was able to master complex, implicit, procedural tasks after his 
surgery, even though he had no recollection of training for such tasks. This implied that 
the hippocampus is necessary for explicit memory formation, but that implicit memories 
are acquired in different systems of the brain. Moreover, the explicit memories he had 
formed before undergoing surgery were still intact, indicating that these had already been 
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consolidated to the cortex, and no longer required a functional hippocampus to be 
recalled. 
The hippocampus is part of the hippocampal formation and includes the dentate 
gyrus (DG), CA1, CA2, and CA3 (Figure 5). The major relay of information between the 
DG and the hippocampal regions by which memory is processed is called the trisynaptic 
circuit. Sensory input first comes in from the entorhinal cortex (EC) to the DG, known as 
the perforant pathway. DG granule neurons then project to CA3 pyramidal cells (mossy 
fiber pathway), and then CA3 neurons project to CA1 (Schaffer collateral projection). 
Finally, CA1 pyramidal cells project to the deep layers of the entorhinal cortex, which 
project back to many of the same cortical areas that originally projected to the entorhinal 
cortex (Barco et al., 2006; Deng et al., 2010). 
Future research has further shown that different subregions of the hippocampus 
control different aspects of behavior. The dorsal/posterior hippocampus is responsible for 
spatial learning and memory. The ventral/anterior hippocampus regulates anxiety 
behaviors. Its role in controlling anxiety is distinct from the role of the amygdala, which 
processes fear-based anxiety (Bannerman et al., 2004). 
Another breakthrough in determining the physiological and molecular 
mechanisms by which memories are formed came from the work of Eric Kandel, through 
his studies of gill withdrawal reflex in model organism Aplysia, a sea mollusk. 
Strengthening or weakening the synapse of the sensory-motor circuit in Aplysia controls 
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the gill withdrawal reflex. For instance, one tap of the siphon results in gill withdrawal, 
but multiple taps cause habituation, which leads to a decrease in neurotransmitter release 
into the synapse and consequent attenuation of the gill withdrawal reflex. Conversely, 
when a tap at the siphon is paired with an aversive stimulus to the tail, sensitization 
occurs whereby interneurons in the tail release additional serotonin into the synapse, 
resulting in increased accumulation of the second messenger cAMP and PKA and 
increased neurotransmitter release along the synapse, leading to greater synaptic strength 
and a more profound gill withdrawal (Castellucci and Kandel, 1976; Castellucci and 
Kandel, 1974). These experiments were of paramount importance in expanding our 
understanding of synaptic plasticity. They showed that neural connections can evolve 
based on context, even in opposite directions. Further studies revealed that an interplay 
between transcriptional activator CREB-1, a downstream target of the cAMP/PKA 
pathway, and transcriptional inhibitor CREB-2, is responsible for the regulation of new 
synaptic connections and thus the formation of new long term memories (Abel et al., 
1998). 
 
Neurotrophins and their Effects on Brain Function 
 
The role of neurotrophins during embryonic development has been studied in 
great detail. Once a neuron has differentiated, its survival depends upon its access to 
neurotrophic factors, which suppress apoptosis in neurons. Most in depth study of 
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neurotrophic factors has been on the family of neurotrophins which include nerve growth 
factor (NGF), brain-derived neurotrophic factor (BDNF), and neurotrophin-3 (NT-3). 
Importantly for the studies detailed in the next two chapters, it appears that both adult 
hippocampal neurogenesis as well as the availability of neurotrophic factors in adults 
may affect cognitive functions (Kandel, 2013). 
In turn, neuronal activity is a powerful regulator of the levels of neurotrophins in 
the brain. The notion that neurotrophic factors are necessary for synaptic plasticity 
came to fruition based on observations that their synthesis and release is activity 
dependent (Chao, 2003). For instance, nerve growth factor (NGF) and brain-derived 
neurotrophic factor (BDNF) messenger RNAs (mRNAs) are regulated in part by electrical 
stimulation and epileptic activity (Gall, 1992). Particularly, BDNF is released due to 
neuronal activity during bouts of activity-dependent synaptic remodeling (Balkowiec and 
Katz, 2002; Kohara et al., 2001). 
Mouse models deficient in neurotrophins have striking phenotypes. Mice that 
globally lack neurotrophins do not survive more than a few weeks postnatally. Those 
that are happloinsufficient for NGF have impaired memory acquisition and retention 
(Chen et al., 1997). Deficiency of BDNF causes increased aggressive behavior, 
hyperactivity and hyperphagia (Kernie et al., 2000; Lyons et al., 1999). BDNF+/– 
mice have abnormal 5-HT mediated neuronal function in the cortex, hippocampus and 
hypothalamus, but treatment with selective serotonin reuptake inhibitors partially 
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corrects the aggressiveness, hyperactivity and hyperphagic phenotypes in these mice 
(Lyons et al., 1999). CamKII-cre-driven conditional deletion of BDNF in the forebrain 
resulted, in addition to hyperphagia and hyperactivity, in increased anxiety measured 
by the light/dark transition test (Rios et al., 2001).  
Importantly, deficiency in BDNF also causes memory deficits. BDNF +/– mice 
have impairments. This is consistent with defects in LTP in the hippocampus, which 
results in deficits in spatial memory (Korte et al., 1995). In Chapter 2.2 of this thesis, 
the effects of osteocalcin signaling in neurons on BDNF levels are explored in several 
mouse models as a potential mechanism by which osteocalcin is able to exert its 
effects on brain functions. 
During my graduate studies, I explored the molecular regulation of cognitive 
function by the hormone osteocalcin. Overall, the identification of peripheral cues 
modulating cognitive function is crucial, as it may open novel therapeutic avenues for 
age-related memory loss and other conditions that affect these functions. Recently, our 
laboratory has provided genetic, molecular, and behavioral evidence that in the mouse, 
osteocalcin, a hormone made only in bone-forming osteoblasts, crosses the blood-brain 
barrier and signals in neurons of the dorsal raphe, ventral tegmental area, and 
hippocampus (Oury et al., 2013b). Osteocalcin favors the synthesis of all monoamine 
neurotransmitters, and inhibits the synthesis of GABA (Oury et al., 2013b) and Ocn-/- 
mice display increased anxiety-like behaviors and poor long-term memory. 
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Neurotransmitter content and cognitive functions are restored by intracerebroventricular 
(ICV) infusions of osteocalcin (Oury et al., 2013b), confirming that it acts locally in the 
brain. Importantly, Ocn-/- mice are not blind and have normal locomotor activity, two 
defects that could have otherwise explained all these phenotypes. The severity of the 
cognitive deficits observed in Ocn-/- mice identifies osteocalcin as a major regulator of 
cognitive function, and calls for the elucidation of the molecular bases of osteocalcin 
signaling in the brain, including the identification and characterization of osteocalcin’s 
receptor in the brain. This information is necessary to explore the therapeutic potential of 










FIGURE 1: MECHANISM OF OSTEOCALCIN PRODUCTION AND ACTIVATION  
   
Figure 1: Mature osteoblasts synthesize and secrete osteocalcin, which is 
carboxylated on 3 glutamic acid residues. When osteoclasts are activated, 
they create resorption lacunae with a pH of 4.5 that simultaneously results 
in osteocalcin decarboxylation. Adapted from Karsenty & Ferron, 2012. 
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FIGURE 2: THE ENDOCRINE REGULATION OF MALE FERTILITY BY BONE  
  
Figure 2: Osteocalcin favors male fertility by binding to a G protein–coupled 
receptor expressed on Leydig cells of the testes, and promoting testosterone 
production in a cAMP response element binding (CREB) protein–dependent manner 
(Karsenty and Oury, 2012). 
 
	  
	   22	  





Figure 3: Sympathetic nervous system activity, which is primary regulated by the 
adipocyte-derived hormone leptin, inhibits bone mass accrual. Brainstem-derived 
serotonin favors bone mass accrual and appetite by acting on sympathetic neurons. 
When leptin crosses the blood brain barrier and binds to its receptor on serotonergic 
neurons in the brainstem, it inhibits serotonin synthesis, which in turn inhibits bone 
mass accrual and appetite, and favors energy expenditure. VMH, ventromedial 
hypothalamus; ARC, Arcuate. From Yadav and Karsenty, 2009. 
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FIGURE 4: OSTEOCALCIN IS NECESSARY FOR ADAPTATION TO EXERCISE 
 
  
Figure 4: Osteocalcin signaling in myofibers favors the uptake and catabolism of 
glucose and fatty acids, which are its main nutrients, and thereby favors adaptation 
to exercise. Osteocalcin signaling in myofibers is also responsible for the majority of 
exercise-induced release of interleukin-6, a myokine which promotes exercise 
adaptation in part by stimulating an increase in circulating bioactive osteocalcin.  
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FIGURE 5: STRUCTURE AND FLOW OF INFORMATION IN THE HIPPOCAMPUS 
	    
Figure 5: A) An illustration of neuronal projections within the hippocampus. B) A 
diagram of the classic excitatory trisynaptic pathway (entorhinal cortex (EC)–
dentate gyrus (DG)–CA3–CA1–EC). The axons of neurons in the EC project to the 
DG through the perforant pathway (PP), including the lateral perforant pathway 
(LPP) and medial perforant pathway (MPP). The DG sends projections to the CA3 
through mossy fibres. CA3 pyramidal neurons convey this information to CA1 
pyramidal neurons through Schaffer collaterals. CA1 pyramidal neurons send back-
projections into deep-layer neurons of the EC. The CA3 also receives projections 
directly from the EC, as does the CA1 (temporoammonic pathway, TA). From Deng 
et al., 2010. 
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Chapter 2. The Regulation of Brain Development and Function 
by Osteocalcin 
 
Part I. Maternal and offspring pools of osteocalcin influence brain 




The results of this study were published in the journal Cell, Volume 155, Issue 1, 
on September 26, 2013. In short, given the obvious passivity of Osteocalcin-deficient 
mice, we asked whether this bone-derived hormone acts as the long sought-after means 
by which the skeleton communicates with the brain. In the first part of this study, we 
examined the impact of maternal osteocalcin on the development of the fetal brain. In the 
second part, we characterized the impact of osteocalcin on the adult brain, including its 
influence on neurotransmitter content and its role in regulating anxiety, depression, and 
memory. 
My contributions to this study include primary hindbrain neuron culture to assess 
osteocalcin activity in vitro, ex vivo explant experiments, binding assays, gene expression 
studies, a portion of the behavioral analysis performed to characterize the Osteocalcin-/- 




	   26	  
Results 
 
Osteocalcin influences the synthesis of several neurotransmitters  
The unusual passivity of the Ocn-/- mice, a feature reported by all investigators 
handling them since they had been generated, was quantified by comparing their 
locomotion to that of wild-type (WT) littermates during light and dark phases or over 30 
minutes of an open field paradigm test (Figure 1A-C). Both assays showed a significant 
decrease in locomotion in 3-month-old Ocn-/- mice. Since this analysis was conducted in 
female mice, this decrease in locomotion could not be ascribed to a lack of sex steroid 
hormones because their synthesis is not regulated by osteocalcin in female mice (Oury et 
al., 2011), nor was it secondary to a measurable deficit in muscle functions (Figure S1A). 
Locomotion was normal in mice lacking Gprc6a, the only known receptor for osteocalcin 
(Figure 1A-C), implying that the passivity of Ocn-/- mice may not be a consequence of 
their metabolic abnormalities since these are equally severe in Ocn-/- and Gprc6a-/- mice 
(Figure S1B-E). This was further addressed by including Gprc6a-/- mice in all 
subsequent experiments. 
To determine if this passivity developing in the face of normal muscular function 
was caused by perturbations in neurotransmitters accumulation in the brain, we measured 
neurotransmitter content in various areas of the brain of 3-month-old WT, Ocn-/-, and 
Gprc6a-/- mice through high-pressure liquid chromatography. This analysis showed that 
GABA content was increased in all brain areas tested in Ocn-/- compared to WT mice 
(Figure 1D). In contrast, norepinephrine and serotonin contents were significantly 
decreased in the brainstem while the one of dopamine was decreased in the midbrain, 
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cortex and striatum of Ocn-/- mice (Figure 1E-G). Glutamate levels were normal in the 
brains of Ocn-/- mice (Figure S1I). The contents of all these neurotransmitters were 
similar in WT and Gprc6a-/- brains (Figure S1F-H). 
An explanation for the changes in neurotransmitter accumulation in Ocn-/- mice 
is that the expression of genes necessary for their synthesis was altered. Expression of 
Gad1 and Gad2, two enzymes required for GABA biosynthesis, was increased in the 
brainstem of Ocn-/- mice (Figure 1H). Expression of Tph2, the gene encoding the initial 
enzyme needed for brain serotonin synthesis (Walther et al., 2003), and of Th that 
encodes the initial enzyme in dopamine and norepinephrine synthesis (Daubner et al., 
2011; Palmiter, 2008) was decreased in the brainstem and midbrain, respectively (Figure 
1H). Conversely, in Esp-/- mice, which display an increase in the circulating levels of the 
undercarboxylated form of osteocalcin (Lee et al., 2007), Tph2 expression in the 
brainstem was increased (Figure S1J). All these genes were normally expressed in 
Gprc6a-/- mice (Figure 1H) further supporting the notion that osteocalcin affects the 
synthesis of neurotransmitters in a Gprc6a-independent manner.  
 
Osteocalcin favors several behaviors 
The increase in the content of GABA and the decrease of monoamine 
neurotransmitters (serotonin and catecholamine) in the brains of Ocn-/- mice should 
hamper their behavior. To determine if it was the case, we conducted several behavioral 
tests in female WT, Ocn-/- and Gprc6a-/- mice.  
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Anxiety-like behavior was analyzed by three conflict-based tests. The dark/light 
transition test exploits the innate aversion of rodents to brightly illuminated areas 
(Crawley, 1985; David et al., 2009). The test apparatus consists of a dark, safe, 
compartment and an illuminated, aversive, one. In this test, three parameters are 
recorded: (i) latency to enter the lit compartment, (ii) time spent in the lit compartment, 
and (iii) the number of transitions between compartments. Ocn-/- mice displayed longer 
latency and spent less time in the lit compartment, two indexes of anxiety-related 
behavior (Figure 2A). They also made fewer transitions between compartments, an index 
of anxiety-like behavior and of motor-exploratory activity (Figure 2A). The next test, the 
elevated plus maze (EPM) test (Holmes et al., 2000; Lira et al., 2003), relies on the 
aversion of rodents to open spaces. The EPM comprises two open and two enclosed arms. 
Testing takes place in bright ambient light conditions. Animals are placed onto the central 
area facing one closed arm and allowed to explore for 5 min. Anxiety-related behavior is 
defined in this test by a lesser proportion of time spent and fewer entries in the open 
arms. This is what was observed in Ocn-/- mice (Figure 2B). In the third test, the open 
field test (OFT) (David et al., 2009), mice are placed in the center of the open field box 
and video-tracked under normal light conditions for 30 min. Ocn-/- mice showed a drastic 
decrease in the distance moved, time spent in the center, and in the vertical activity 
compared to WT littermates, all features indicative of greater anxiety-like behavior and 
decreased exploratory activity (Figure 2C).  
 
Anxiety is often accompanied by depression. This was first assessed by the tail 
suspension test in which animals are subjected to the inescapable stress of being 
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suspended by their tails (Cryan et al., 2005; David et al., 2009). In this test, an index of 
helplessness is the time spent immobile. This time was significantly increased in Ocn-/- 
mice (Figure 2D). In the forced swim test, mice are forced to swim over 6 minutes in a 
glass cylinder filled with water from which they cannot escape. Over time, mice cease 
their attempts to escape and float passively, an indication of a depression-like behavior. 
Ocn-/- mice spent 45% more time floating than WT mice (Figure 2E).  
Spatial learning and memory were assayed through the Morris water maze test 
(MWM) that is thought to reflect functions of the hippocampus. This test relies on the 
ability of mice to use spatial cues to locate a submerged platform. Spatial learning is 
assessed through 4 trials a day for 10 to 12 days. Ocn-/- mice showed a near complete 
inability to learn over the course of 10 days (Figure 2F). Taken together, these tests 
showed that osteocalcin exerts a significant influence on anxiety, depression-like 
behaviors, learning and memory. An electroretinogram did not detect any difference 
between Ocn-/- and WT mice thus ruling out that these behavioral abnormalities were 
secondary to blindness (Figure S2A). Gprc6a-/- mice were indistinguishable from WT 
littermates for all these tests (Figure 2A-E and G). 
 
 
Osteocalcin signals in discrete areas of the brain  
The fact that the molecular and behavioral abnormalities observed in Ocn-/- were 
not seen in Gprc6a-/- mice ruled out that they were simply a consequence of the 
metabolic disturbances of Ocn-/- mice and suggested that osteocalcin might signal in the 
brain. 
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To answer this question, we first tested if osteocalcin could cross the blood brain 
barrier (BBB). For that purpose we delivered subcutaneously vehicle or recombinant 
uncarboxylated, full-length, mouse osteocalcin (hereafter referred to as osteocalcin) in 3 
month-old Ocn-/- mice.  As a positive control, leptin, which crosses the BBB (Banks et 
al., 1996), was delivered in the same conditions in 3 month-old ob/ob mice. Seven days 
later, leptin and osteocalcin contents were measured in the blood and various parts of the 
brain of ob/ob and Ocn-/- mice, respectively. As expected, leptin was detected in the 
brainstem and hypothalamus of ob/ob mice (Yadav et al., 2009) (Figure S3A), as for 
osteocalcin it accumulated in the brainstem, thalamus and hypothalamus of Ocn-/- mice 
(Figure 3A). In the conditions of this assay the quantity of osteocalcin that accumulated 
in each location in the brains of Ocn-/- mice was similar to that observed in the brains of 
WT mice (Figure 3A and S3B). When using carboxylated, full-length, mouse osteocalcin 
(hereafter referred to as carboxylated osteocalcin) significantly less of the hormone 
accumulated in the brainstem and hypothalamus and none in the midbrain (Figure 3A).  
 
To determine if osteocalcin binds to neurons we incubated sections of adult 
mouse brains with biotinylated uncarboxylated osteocalcin (300ng/ml) or GST-biotin 
alone (1.5mg/ml) followed by immunofluorescence analysis with an anti-biotin antibody. 
In the midbrain, osteocalcin bound to neurons in the ventral tegmental area, a nucleus 
located close to the midline on the floor of the midbrain and enriched in dopaminergic 
neurons; in the brainstem binding was detected in the dorsal and median raphe nuclei that 
contain serotonergic neurons, in the hippocampus osteocalcin bound to neurons of the 
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CA3 region of the hippocampus (Figure 3B). In each location, this binding was specific 
since it was displaced by unlabeled osteocalcin (Figure 3B).   
We then asked ex vivo if osteocalcin could signal in neurons to influence 
expression of genes needed for neurotransmitter synthesis. Brains were sliced at the level 
of the median and dorsal raphe of the brainstem so that they would be enriched in 
serotonin-producing neurons, or at the level of the substantia nigrae and ventral tegmental 
areas (VTA) of the midbrain. Osteocalcin decreased Gad1 expression, increased Tph2 
and Th expression in brainstem and midbrain explants respectively regardless of their 
genotypes (Figure 3C). Osteocalcin also decreased Gad1 expression by 65% and 
increased Tph2 expression 3 folds when added to primary hindbrain neuron cultures 
(Figure 3D). Osteocalcin influenced gene expression in a dose-dependent manner but 
with different optimal concentrations for each gene tested (Figure S3C). Two more 
assays confirmed that osteocalcin could signal in neurons of the brainstem. First, 
osteocalcin (30ng/ml) induced calcium flux in hindbrain neurons collected at embryonic 
day 14.5 (E14.5) (Figure 3E); second, whole-cell current clamp recording showed that 
osteocalcin could activate the action potential frequency of neurons in the brainstem and 
the locus coeruleus (Figures 3F and S3D). Osteocalcin also inhibited the action potential 
frequency of the GABAergic interneurons of the brainstem, recognized by eGFP labeling 
using the glutamate decarboxylase (GAD)67-GFP knock-in mouse model (Tanaka et al., 
2006) (Figure 3G).  
Lastly, we asked if osteocalcin acts in the brain in vivo to affect gene expression 
and behaviors. For that purpose, we delivered the hormone via intracerebro-ventricular 
(ICV) infusions (10ng/hour) to Ocn-/- mice (Figure S4A). Measurements of osteocalcin 
	  
	   32	  
in the blood of infused Ocn-/- mice showed that there was no leakage of the centrally 
delivered molecule into the general circulation (Figure S4B). This week-long treatment 
normalized Tph2, Th, Gad1 and Gad2 expression, corrected fully anxiety and depression 
and partially corrected the spatial learning and memory defect in Ocn-/- mice (Figures 
4A-F and S4C). Collectively, results of these ex and in vivo assays indicate that 
osteocalcin regulates neurotransmitter synthesis and behaviors in the mouse by directly 
acting in the brain.  
In view of the results presented above, we verified that there was no cryptic 
expression of Ocn in the brain. For that purpose, we relied on qPCR, in situ hybridization 
and mCherry detection in adult mice in which the mCherry reporter gene had been 
knocked in the Ocn locus (Oury et al., 2011). There was no detectable expression of Ocn 
in any part of the WT mouse brain above what was seen in Ocn-/- brains and no 
detectable signal in Ocn-mcherry brains (Figure 4G-H and Figure S4D,E).  
 
Osteocalcin signals in the brain post-natally 
In the next experiment we asked whether osteocalcin influences behaviors and 
neurotransmitter synthesis by acting post-natally. To address this question we crossed 
mice harboring a floxed allele of Ocn with mice expressing CreERT2 under the control of 
the osteoblast-specific regulatory elements of the mouse a1Col1 gene (OcnosbERT2) (Kim 
et al., 2004). OcnosbERT2 mice showed a significant reduction (52%) of osteocalcin 
circulating levels following treatment with tamoxifen, thus verifying that we had 
efficiently, even if partially, inactivated this gene (Figure S5A). 
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Six week-old a1Col1-CreERT2, Ocnflox/flox, and OcnosbERT2 mice were injected daily 
with tamoxifen (1mg/20g of body weight) for 1 week, and every 3 weeks to ensure that a 
stable deletion of Ocn was achieved. These mice were analyzed 6 weeks later. 
Tamoxifen-treated OcnosbERT2 mice showed a significant decrease in locomotion and an 
increase in anxiety- and depression-like behaviors compared to a1Col1-CreERT2 or 
Ocnflox/flox, mice (Figure 5A-E). Gad1 and Gad2 expression was increased in tamoxifen-
treated OcnosbERT2 mice; this defect was partially corrected upon osteocalcin ICV infusion 
(Figure 5F). There was also a decrease in the content of serotonin and norepinephrine in 
the brainstem and of dopamine in the striatum of OcnosbERT2 mice (Figure 5G). Hence, 
osteocalcin acts post-natally to affect neurotransmitter synthesis and behaviors. 
 
Maternal osteocalcin is needed for proper fetal brain development  
The most informative aspect of the experiment presented above, however, was 
that OcnosbERT2 mice differed from Ocn-/- mice in two critical respects. First, spatial 
learning and memory were less severely affected in tamoxifen-treated OcnosbERT2 than in 
Ocn-/- or even Ocn+/- mice (Figure 5H). Second, the near absence of the corpus 
callosum and the marked decrease in the area of the dentate gyrus noted in all Ocn-/- 
mice analyzed were never seen in tamoxifen-treated OcnosbERT2 mice (Figure 5I). These 
observations prompted us to ask if osteocalcin influences fetal brain development. 
qPCR analysis of its expression during development between E13.5 and E18.5, 
showed that Ocn starts to be expressed in the developing skeleton at E16.5 and is not 
expressed anywhere in the brain at any of these developmental stages (Figures 6A, S6A 
and S6B). The same was true when analyzing Ocn-mCherry embryos (Figure S6C). 
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Surprisingly however, osteocalcin was readily measured in the blood of E14.5 embryos 
i.e., 2 days before expression of the gene becomes detectable (Figure 6B). Since Ocn is 
not expressed in the placenta (Figure 6A), the only explanation for this observation was 
that maternal osteocalcin reaches the fetal blood stream. An ex vivo dual perfusion system 
that monitors the transport of substances across the mouse placenta (Goeden and Bonnin, 
2013) showed that osteocalcin could cross the placenta starting at E14.5 (Figure 6C). A 
larger transfer of maternal osteocalcin to the fetal circulation was observed at E15.5 and 
E18.5 (Figure 6C). In this assay, carboxylated osteocalcin did not cross the placenta of 
pregnant mice at day 18.5 of gestation (Figure S6D).  
To ascertain that osteocalcin crosses the placenta in vivo we measured its serum 
levels in embryos of various genotypes and origins. That osteocalcin was detectable in 
the serum of E18.5 Ocn-/- embryos carried by Ocn+/- mothers established that maternal 
osteocalcin crosses the placenta in vivo (Figures 6D and S6E). Still at E18.5, osteocalcin 
circulating levels were up to 45% lower in WT embryos when their mothers were Ocn+/- 
than when their mothers were WT (Figures 6D and S6E). Likewise, osteocalcin 
circulating levels in E18.5 Ocn+/- embryos were 45% decreased when mothers were 
Ocn-/- compared to WT mothers (Figures 6D and S6E). In E16.5 embryos, osteocalcin 
circulating levels in WT embryos carried by WT mothers were 7.2ng/ml, but 
undetectable in embryos of any genotype carried by Ocn+/- mothers (Figure 6D). In all 
E18.5 embryos and their mothers the circulating levels of the carboxylated and 
uncarboxylated forms of osteocalcin were measured through a specifically designed 
ELISA (Ferron et al., 2010) (Figure S6E and S6F). These results indicate that maternally 
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derived osteocalcin contributes to the majority of the pool of this hormone present in the 
serum of embryos at E16.5 and E18.5. 
To determine the nature of the influence of maternal osteocalcin on fetal brain 
development, we relied on histology and cell biology approaches. Regardless of the 
genotype of the mothers, there was no difference in the ratio of brain weight over body 
weight between WT and Ocn-/- embryos at E16.5 (Figure S6G). By contrast, when 
compared to WT embryos carried by WT mothers, this ratio was markedly decreased in 
E18.5 Ocn-/- embryos if mothers were Ocn-/- mothers but not if they were Ocn+/- 
(Figure S6H). Cresyl violet staining of histological sections showed an enlargement of 
the cerebral ventricles in the brains of E18.5 Ocn-/- embryos originating from Ocn-/- 
mothers compared to what was seen in WT embryos originating from WT mothers. This 
enlargement was not seen either in Ocn-/- embryos originated from Ocn+/- mothers 
(Figure 6E). The absence of osteocalcin in embryos also caused neuronal apoptosis of 
different severity depending on the genotype of the mothers. Specifically, a TUNEL 
assay showed a two-fold increase in the number of apoptotic cells in the hippocampus of 
E18.5 Ocn-/- embryos compared to WT embryos originating from WT mothers only if 
their mothers were Ocn-/- (Figure 6F and S6I). Neuronal apoptosis was not seen 
throughout the brain and for instance was absent in the septal nuclei of Ocn-/- mice 
(Figure S6J). These results indicate that maternal osteocalcin affects fetal neurogenesis. 
 
Maternal osteocalcin influences spatial learning and memory and neurogenesis in 
adult offspring 
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The influence of maternal osteocalcin on fetal neurogenesis led us to test whether 
this pool of the hormone also affects cognition and neurogenesis in the adult offspring.  
 
Given the massive apoptosis observed in the hippocampal region, we first asked, through 
the use of a 3-shock contextual fear-conditioning paradigm (CFC), if the learning deficit 
revealed in Ocn-/- mice in the MWM test could be better linked to the hippocampus; and, 
if its severity was influenced by the genotype of their mothers. Ocn-/- mice born from 
Ocn-/- mothers exhibited significantly less context-elicited freezing than WT or Ocn-/- 
mice born from Ocn+/- mothers in the context A and a similar context A’ (Figure 6G). 
Next, we used a modified version of the novel object recognition (NOR) paradigm 
(Ennaceur and Delacour 1988; Denny et al., 2012) that assesses the rodent’s ability to 
recognize a novel object in the environment. General activity (grid crossings) and object 
investigation (averaged across the two objects) were assessed during two exposures. In 
the first one, mice were exposed to two objects; while in a second one, they faced a 
constant and a novel object. There was no difference in object investigation during 
exposure 1 between the various groups of mice, indicating that their genotype did not 
affect behavior prior to introducing a novel object (Figure 6H). The main parameter 
assessed in the second period was the time spent for exploration of the novel object. A 
longer exploratory period betrays a hippocampal deficit in 129sv/ev mice (Denny et al., 
2012). This is what was observed in Ocn-/- mice born from Ocn-/- mothers compared to 
Ocn-/- mice born from Ocn+/- mothers or WT mice (Figure 6H). Hence, both tests 
suggest a hippocampal origin to the spatial learning and memory defects seen in Ocn-/- 
mice.  
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To determine if this deficit in spatial learning and memory was associated with an 
impairment of adult neurogenesis in the hippocampus, we performed BrdU staining and 
doublecortin (DCX) immunohistochemistry in the hippocampal region of 3-month-old 
mice.  There was a significant reduction in the number of DCX+ and BrdU+ neurons in 
Ocn-/- mice compared to WT mice regardless of the genotype of the mothers; this 
reduction, however, was more severe if mothers were Ocn-/- (Figures 6I and 6J). Hence, 
the maternal pool of osteocalcin is necessary for hippocampus-dependent learning in 
adult mice in part because it also affects adult hippocampal neurogenesis. 
Taken together the analyses presented above of the functions of the maternal pool 
of osteocalcin implied that delivering the hormone to Ocn-/- females during their 
pregnancy could normalize hippocampal neurogenesis in Ocn-/- embryos and might 
improve behaviors in adult Ocn-/- offspring. These two points were tested following 
once-a-day injections of osteocalcin (240ng/day) to pregnant Ocn-/- females mated with 
Ocn-/- males from E0.5 to E18.5. Neither mothers nor pups received the hormone after 
birth.  
This treatment had mild effect on parameters of anxiety or depression (except in 
the OFT) in 3-month-old Ocn-/- offspring, but rescued almost entirely their deficit in 
learning and memory (Figure 7A-F). To explain this striking rescue of spatial learning 
and memory we conducted histological and biochemical analyses. The enlargement of the 
cerebral ventricles and the increase in neuronal apoptosis seen in the brains of E18.5 
Ocn-/- embryos carried by Ocn-/- mothers were absent if these mothers had been injected 
with osteocalcin throughout their pregnancy (Figure 7G,H), and a Western blot analysis 
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showed a decrease in Caspase-3 cleaved levels in hippocampi of Ocn-/- embryos carried 
by osteocalcin-injected Ocn-/- mothers (Figure S7A). In 3-month-old offspring, cresyl 
violet staining and NeuN immunofluorescence showed a normalization of the area of the 
dentate gyrus in the hippocampus of Ocn-/- mice originating from osteocalcin-injected 
Ocn-/- mothers (Figure 7I). Likewise, the contents of serotonin and norepinephrine were 
similar in 3-month-old WT and Ocn-/- mice born from osteocalcin-injected Ocn-/- 
mothers (Figure 7J); the content of dopamine that was low in the striatum of Ocn-/- mice 
(Figure 1F) was also normalized in Ocn-/- mice born from osteocalcin-injected Ocn-/- 
mothers (Figure 7J). GABA levels remained elevated in the offspring of osteocalcin-
injected Ocn-/- mice albeit not significantly (Figure 7K). These experiments indicate that 
the maternal pool of osteocalcin is necessary for the acquisition of learning- and memory-
like behaviors in the adult offspring in part because it prevents neuronal apoptosis in the 
hippocampus. 
This study was triggered by, on the one hand, the existence of a central control of 
bone mass and the need to understand how bone itself could regulate it; and on the other, 
by the abnormal passivity of the Osteocalcin-deficient mice. This is why we asked 
whether the bone-derived hormone osteocalcin could provide this elusive missing link 
between the skeleton and the brain and regulate brain development during embryogenesis 
and behavioral functions during adulthood. In testing these two hypotheses, we observed 
that Ocn-/- mice display a very significant increase in anxiety and depression and 
profoundly impaired learning and memory when compared to WT littermates. We 
showed that in mice, Osteocalcin is not expressed in any part of the WT brain at any 
point before or after birth and bone-derived osteocalcin which crosses the blood-brain 
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barrier, accumulates in discrete parts of the brain, including the hippocampus, and binds 
to several neuronal populations to influence molecular and physiological events.  
Specifically, osteocalcin favors the synthesis of monoamine neurotransmitters 
(serotonin, dopamine, and norepinephrine) and impedes the synthesis of the inhibitory 
neurotransmitter, GABA. It does so independently of its peripheral receptor, Gprc6a, 
which is not expressed in regions of the brain where osteocalcin acts. Moreover, Gprc6a-
/- mice do not display the behavioral phenotype observed in Ocn-/- mice. We also 
showed that the absence of maternal osteocalcin during embryogenesis impairs brain 
development, resulting in defects of spatial learning and memory in the offspring in 
adulthood. This latter part is important as it led to the development of a new line of 
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FIGURE 3. OSTEOCALCIN BINDS TO NEURONS IN THE BRAIN 
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FIGURE 7. MATERNAL OSTEOCALCIN DETERMINES SPATIAL LEARNING AND 
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FIGURE S3. OSTEOCALCIN BINDS TO NEURONS IN THE BRAIN 
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FIGURE S7. MATERNAL OSTEOCALCIN DETERMINES SPATIAL LEARNING AND 
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Figure Legends 
Figure 1: Osteocalcin affects the biosynthesis of neurotransmitters  
Measurements of (A) total (XTOT) and (B) ambulatory activity (AMBX), in Ocn-/- and 
Gprc6a-/- mice, during 12h light and dark phases over 3 days. Mutant mice were 
compared to their WT littermates. (C) Video tracking of an open field paradigm test 
performed in Ocn-/-, Gprc6a-/- and WT littermate mice. (D) GABA,  (E) serotonin, (F) 
dopamine, and (G) norepinephrine contents in various parts of the brains of Ocn-/- and 
WTmice. (H) Expression (qPCR) of Tryptophan hydroxylase-2 (Tph2), Glutamate 
decarboxylase-1 and -2 (Gad1), (Gad2) and Tyrosine hydroxylase (Th) in the brainstem 
and midbrain of Ocn-/-, Gprc6a-/- and control mice.  
 
Figure 2: Osteocalcin affects several behaviors 
 
 (A) Light and Dark test (L/DT): The latency (Sec) to enter the lit compartment, number 
of transitions between compartments and time spent in the lit compartment were 
measured. (B) Elevated Plus Maze test (EPMT): Number of entries and time spent (Sec) 
in the open arms were scored. (C) Open field test (OFT): Total distance (cm), % of the 
distance traveled in the center versus periphery, % of the time spent in the center versus 
periphery and number of rearing events were measured. The video tracking of each group 
of mice is represented on the right panel. (D-E) Representation of the time spent (Sec) 
immobile during the (D) Tail Suspension test and (E) the Forced Swim test. Both tests 
assess depression-like behavior. (F-G) Morris Water Maze test performed over 12 days. 
The graphic shows the time (seconds) needed for each group of mice to localize a 
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submerged platform in the swimming area. The video tracking on the left panel 
represents the standards obtained for each group analyzed. (a) * means P value of  < 0.05 
versus WT. 
 
Figure 3: Osteocalcin binds to neurons in the brain 
(A) Measurement of osteocalcin in bone, serum, cortex, midbrain, hypothalamus and 
brainstem of Ocn-/- mice receiving either PBS (first column), uncarboxylated (second 
column), or carboxylated (third column) osteocalcin s.c. during 7 days. (B) Binding of 
GST-biotin (1.5mg/ml) (panel 1) and biotinylated uncarboxylated osteocalcin (300ng/ml) 
(panels2-4) to the dorsal (DR) (first row) and median (MR) (second row) raphe nuclei of 
the brainstem (identified by anti-5-HT immunofluorescence), to the ventral tegmental 
area (VTA) (third row) of the midbrain (identified by anti-TH immunofluorescence) and 
to the CA3 region (fourth row) of the hippocampus (identified anatomically). Panels 5: 
competition with unlabeled osteocalcin (1000-fold excess). (C) Expression of Tph2 and 
Gad1 in brainstem, of Th in midbrain explants from WT and Gprc6a-/- mice, treated with 
3ng/ml osteocalcin or vehicle. (D) Gene expression in mouse primary hindbrain neurons 
treated with osteocalcin (10ng/ml) or vehicle. (E) Calcium flux of hindbrain neurons 
responsive (n=7) and unresponsive (n=5) to osteocalcin (30ng/ml). (F-G) Extracellular 
current recordings of (F) neurons of the dorsal raphe nucleus and (G) GABAergic 
interneurons of the brainstem treated with osteocalcin (10ng/ml).  
 
Figure 4: Osteocalcin signaling in the brain prevents anxiety and depression  
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 (A) Light and Dark, (B) Elevated plus maze, (C) Open field, (D) Forced Swim and (E) 
Tail suspension tests performed in WT (n=7) and Ocn-/- mice infused with vehicle (n=7) 
or osteocalcin (10ng/hour) (n=7). (F) Expression (qPCR) of Tph2, Gad1 and Gad2 in 
brainstem, and Th in midbrain of WT (n=6) and Ocn-/- mice infused with vehicle (n=6) 
or uncarboxylated mouse osteocalcin (10ng/hour) (n=7). (G) Gene expression analysis 
(qPCR) in bone and in the cortex, striatum, hippocampus, hypothalamus, midbrain, 
brainstem and cerebellum in WT and Ocn-/- mice. (H) In situ hybridization of Ocn in 
WT and Ocn-/- adult brain (sagittal sections are represented) and in WT bone as a 
control.   
 
Figure 5: Osteocalcin regulates brain functions post-natally  
 
 (A) Light and dark, (B) Elevated plus maze, (C) Forced Swim, (D) Open field, (E) Tail 
suspension and (H) Morris Water maze tests performed in a cohort of Ocnflox/flox , a1Col1-
CreERT2 and OcnosbERT2  mice.  (F) Expression (qPCR) of Gad1 and Gad2 in brainstem 
and striatum of Ocnflox/flox , a1Col1-CreERT2 and OcnosbERT2  mice. (G) HPLC analysis of 
serotonin, dopamine and norepinephrine contents in brainstem, midbrain and striatum of 
Ocnflox/flox, a1Col1-CreERT2 and OcnosbERT2 mice. (I) Cresyl violet staining and NeuN 
immunofluorescence of control Ocn-/- and OcnosbERT2  hippocampi. The dentate gyrus 
area (% versus WT) is represented in the right panel. In each panel (A-F and H), “Total 
Control” means a1Col1-CreERT2 and Ocnflox/flox mice combined.  
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Figure 6: Maternal osteocalcin favors fetal neurogenesis 
 
(A) Expression of Ocn (qPCR) in bone, brain and placenta of WT and Ocn-/- newborn 
(P0) and embryos (E13.5 to E18.5). (B) Osteocalcin circulating levels in WT or Ocn-/- 
newborns (P0) and embryos (E13.5 to E18.5). (C) Ex vivo dual perfusion system that 
monitors the transport of osteocalcin across the placenta. Uncarboxylated mouse 
osteocalcin (300 ng/ml) was injected through the uterine artery in placentas obtained 
from WT mice at E14.5, 15.5, and 18.5 of pregnancy. Osteocalcin in fetal eluates is 
represented as % of maternal input. (D) Circulating levels of osteocalcin in WT embryos 
originating from WT or Ocn+/- mothers, of Ocn+/- embryos originating from Ocn+/- or 
Ocn-/- mothers and of Ocn-/- embryos originating from Ocn+/- or Ocn-/- mothers. 
Measurements were performed at E16.5 and E18.5. (E) Cresyl violet stain of lateral 
ventricles of hippocampi of E18.5 WT embryos originating from WT mothers and Ocn-/- 
embryos originating from Ocn+/- or Ocn-/- mothers. The measurements of the lateral 
ventricle area over brain area are represented below the images (in %). (F) Number of 
apoptotic cells (stained by TUNNEL assay) in hippocampi of E18.5 WT embryos carried 
by WT mothers and Ocn-/- embryos carried by Ocn+/- or Ocn-/- mothers. (G-H) 
Contextual fear conditioning (CFC) (G) and novel object recognition (NOR) (H) 
performed in WT and Ocn-/- mice born from Ocn-/- or Ocn+/- mothers (n = 7-18 per 
group). In the CFC, Ocn-/- mice born from Ocn-/- mothers mice exhibited significantly 
less context-elicited freezing than WT mice in context A and A’. In the NOR, there was a 
significant increase in the exploratory period in Ocn-/- mice born from Ocn-/- mothers 
compared to Ocn-/- mice born from Ocn+/- mothers or WT mice when a novel object 
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was introduced. (I-J) BrdU and DCX Immunohistochemistry showing a significantly 
lower number of BrdU+ (I) and DCX+ (J) cells in the dentate gyrus (DG) of WT and 
Ocn-/- mice born from Ocn-/- or Ocn+/- mothers. This decrease was even more 
pronounce in the ventral region of the DG. (*) P value < 0.05, (**) P value < 0.01, (***) 
P value < 0.001.  
 
Figure 7: Maternal osteocalcin determines spatial learning and memory in adult 
offspring 
(A) Light and Dark, (B) Elevated plus maze, (C) Open field, (D) Forced Swim, (E) Tail 
suspension and (F) Morris Water maze tests performed in 3 month-old Ocn-/- mice born 
from Ocn-/- mothers injected once a day with vehicle or osteocalcin (240ng/day) during 
pregnancy compared to WT mice. (G) Surface of the lateral ventricle over brain area (%) 
of E18.5 hippocampi coronal sections of WT embryos originating from WT mothers and 
Ocn-/- embryos originating from osteocalcin-injected Ocn-/- mothers. (H) Number of 
apoptotic cells (stained by TUNNEL assay) of E18.5 hippocampi coronal sections of WT 
embryos originating from WT mothers and Ocn-/- embryos originating from Ocn-/- 
mothers injected with osteocalcin (240ng/day). (I) Cresyl violet, NeuN 
immunofluorescence and dentate gyrus area (% versus WT) of WT and Ocn-/- 
originating from osteocalcin-injected Ocn-/-. (J-K) HPLC measurements of serotonin (J), 
norepinephrine (NE) (J) content in the brainstem; dopamine content in the striatum (J), 
and GABA content in the brainstem, midbrain and striatum (K) of WT and Ocn-/- 
originating from osteocalcin-injected Ocn-/- mothers. (a) means P value of  < 0.05 versus 
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WT, (b) mean P value of  < 0.05 versus Ocn-/- originating from Ocn-/- mothers injected. 
Supplementary Figure Legends 
Figure S1 
(A) Treadmill analysis of Ocn-/- (n=8) and their littermates control (n=7). The different 
panels represent, the percentage of the mice running according to an increase of the 
maximal speed (cm/s), the average of the maximal speed run by each group  (cm/s), of 
the total running distance (m) and of the time on treadmill (min) for each group. (B-E) 
Energy expenditure analyses of Ocn-/- (n=6), Gprc6a-/- (n=6) and littermate controls 
(n=6). (B) Heat production (Kcal/Hour), (C) oxygen consumption (VO2) (ml/Kg/Hour), 
(D) Carbon dioxide production (VCO2) (ml/Kg/Hour) and (E) the respiratory exchange 
ratio (RER) corresponded to the ratio between carbon dioxide production and oxygen 
consumption (RER= VCO2/VO2). (F-H) HPLC measurements of the content of (F) 
serotonin (ng/mg), (G) norepinephrine (NE), (H) dopamine (ng/mg) in various part of the 
brain (midbrain, brainstem, hippocampus, striatum, cortex) of Gprc6a-/- (n=7) and 
littermate controls (n=6). (I) HPLC measurement of the glutamate content in cortex, 
hippocampus (hippo), striatum, hypothalamus (hypo), midbrain, brainstem, cerebellum 
and total brain in Ocn-/- (n=8) and WT (n=8) littermate mice. (J) Expression analysis 
(qPCR) of Tph2 in brainstem of Esp-/- (n=6) and WT (n=6) littermate mice.  
Figure S2 
(A) Corneal electroretinogram (ERG) elicited by a strobe flash from dark-adapted WT 
and Ocn-/- mice. B-wave peak amplitudes in microvolts (µV) were recorded from both 
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eyes simultaneously. (OD: right eye; OS: Left eye) (Normal range: 500-600 µV) 
 
Figure S3 
(A) Measurement of leptin in serum (ng/ml) and in cortex, midbrain, hypothalamus, 
brainstem (ng/mg) of ob/ob (n=3) mice infused subcutaneously (s.c.) with leptin (right 
panel) or PBS (left panel) for 7 days. (B) Measurement of osteocalcin in serum, bone, 
cortex, midbrain, hypothalamus and brainstem of WT (n=3) compared to Ocn-/- (n=3) 
mice. (C) Expression of Tph2 and Gad1 in brainstem, of Th in midbrain explants from 
WT mice untreated or treated (for 4 hours) with 0.3, 3, 1, 10, 30, 100ng/ml osteocalcin or 
vehicle (n=4 for each conditions). (D) Extracellular current recordings and action 
potential firing rate (% versus WT) of locus coeruleus neurons of the brainstem treated 
with osteocalcin (10ng/ml). (*) P value < 0.05. 
 
Figure S4 
(A) Coronal sections of WT brain (6 months old) infused by intra-cerebro-ventricular 
(icv) with methylene blue stain showing diffusion throughout all of the brain represented 
by blue staining in all of the ventricles of the brain. The bregma is indicated on the left 
corner of each picture according to the mouse brain in stereotaxic coordinates by 
Franklin, K.B.J and Paxinos, G. The red arrows represent the location of the icv pump in 
the lateral ventricle. (B) ELISA measurement of circulating osteocalcin content (ng/ml) 
in serum of WT (n=7) and Ocn-/- infused by icv with vehicle (PBS) (n=7) or Ocn-/- 
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infused with osteocalcin (n=7) (10ng/hour). (C) Morris Water Maze test performed over 
10 days in WT (n=7) and Ocn-/- mice infused with vehicle (n=7) or osteocalcin 
(10ng/hour) (n=7). The graphic shows the time (seconds) needed for each group of mice 
to localize a submerged platform in the swimming area. (a) means P value of  < 0.05 
versus WT infused with PBS, (b) mean P value of  < 0.05 versus Ocn-/- infused with 
osteocalcin (10ng/hour). (D) Gene expression analysis (qPCR) in bone and in the cortex, 
striatum, hypothalamus, hippocampus, brainstem, midbrain and cerebellum in adult WT 
(n=9) and Ocn-/- (n=9) mice. This figure shows in logarithmic scale the same values 
represented in Figure 4G. (E) Analysis of mCherry fluorescent protein reflecting Ocn 
expression in bone (tibia and calvaria) and brain of adult Ocn-mCherry mice. The first 
row represents the bright field images. The second row shows the mCherry fluorescence 
protein in red.   
 
Figure S5 
(A) ELISA measurement of circulating osteocalcin in a cohort of Ocnflox/flox (n=9), 
a1Col1-CreERT2 (n=9) and OcnosbERT2 mice (n=11). The level of circulating Ocn is 
represented in % versus WT content.  
 
Figure S6 
(A) Expression of Ocn (qPCR) in bone, brain and placenta of WT and Ocn-/- newborn 
(P0) and embryos (E13.5 to E18.5). This figure shows in logarithmic scale the same 
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values represented in Figure 6A. (B) Gene expression analysis (qPCR) in bone and in the 
cortex, hypothalamus, hippocampus, brainstem, midbrain and cerebellum in E18.5 WT 
(n=3) and Ocn-/- (n=3) embryos. (C) Staining for mCherry fluorescent protein reflecting 
Ocn expression in tibia (first column), calvaria (second column) and brain (third column) 
of E18.5 Ocn-mCherry embryos. The first row represents the brightfield images. The 
second row shows the mCherry fluorescence protein in red.  (D) Ex vivo dual perfusion 
system that monitors the transport of osteocalcin across the placenta. Carboxylated mouse 
osteocalcin (300 ng/ml) was injected through the uterine artery in placentas obtained 
from WT mice at 18.5 of pregnancy. Osteocalcin in fetal eluates is represented as % of 
maternal input (n=2). (E-F) Circulating levels of total (TOTAL), carboxylated (GLA13), 
uncarboxylated (GLU13) osteocalcin and in E18.5 embryos (E) and pregnant mothers 
mice (F): WT embryos originating from WT (n=16) or Ocn+/- mothers (n=6), of Ocn+/- 
embryos originating from WT (n=6), Ocn+/- (n=10) or Ocn-/- (n=10) mothers and of 
Ocn-/- embryos originating from Ocn+/- (n=8) or Ocn-/- (n=6) mothers. For each 
genotype, the embryos were collected from several litters. (G-H) Brain weight (g) over 
body weight (g) of E16.5 (G) and E18.5 (H) WT embryos originating from WT or 
Ocn+/-mothers, E16.5 Ocn+/- embryos originating from WT or Ocn+/- mothers, and 
E16.5 Ocn-/- embryos originating either from Ocn-/- or Ocn+/- mothers. (Total WT) 
represents WT embryos originating from either WT or Ocn+/- mothers, (Total Ocn-/-) 
represents Ocn-/- embryos originating from Ocn-/- and Ocn+/- mothers, (Total Ocn+/-) 
are the embryos originating from WT and Ocn+/- mothers. (I) Coronal section of the 
hippocampus of WT and Ocn-/- originated from Ocn-/- mothers E18.5 brain stained 
using TUNNEL assay. (J) Number of apoptotic cells (stained by TUNNEL assay) 
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(number per mm2) in septal nuclei coronal sections of E18.5 WT embryos originating 
from WT mothers (n=4) and Ocn-/- embryos originating from Ocn-/- mothers (n=4). (*) 
P value < 0.05, (**) P value < 0.01, (***) P value < 0.001. 
 
Figure S7: 
(A) Western-blot analysis of cleaved Caspase-3 in the hippocampus from pools of 3 
E18.5 WT, 3 Ocn-/-, and 3 Ocn-/- embryos originating from Ocn-/- mothers receiving 
vehicle or osteocalcin (240ng/day) during pregnancy. 
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Part II. Osteocalcin is necessary and sufficient to reverse the decline in 
cognitive functions caused by aging 
 
Preface 
The first study raised novel questions, including whether bone health is a 
significant determinant of cognition in otherwise wild type mice. A second question, 
given the natural history of circulating osteocalcin levels during adulthood, is whether 
exogenous osteocalcin might be sufficient to reverse age-related cognitive decline. 
Another reason to ask these questions is that [3H]-osteocalcin binds to the amygdala and 
hippocampus in humans as it does in mice (Oury et al., 2013b). While binding is 
homogeneous in multiple subnuclei in the amygdala, it is greater in the hilus and CA3 
region of the hippocampus (Fig. 1a-b). 
In addressing the first question, during my graduate studies, I have accumulated 
experimental evidence indicating that impairment in either bone formation or bone 
resorption indeed exerts a significant negative influence on both anxiety and memory. 
Specifically, Runx2+/- mice, which have a decrease in bone formation and, consequently, 
low circulating bioactive osteocalcin levels, have increased anxiety and defects in 
memory. On the other hand, when we treated mice with alendronate, a small molecule 
inhibitor of bone resorption, these mice also had impairments in anxiety and memory. 
Remarkably, these deficits were fully rescued by exogenous peripheral delivery of 
osteocalcin. In view of these results, and since circulating osteocalcin levels rise during 
exercise, we asked whether osteocalcin contributes to the cognitive improvement that 
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occurs after exercise. My work shows that in the absence of osteocalcin, mice are unable 
to improve cognitive functions after 5 weeks of voluntary exercise, indicating that 
osteocalcin is a necessary factor in the improvement in cognition upon exercise.  
These results were an incentive for me to ask other physiological questions. In 
particular, recent studies have shown a reversal in age-related cognitive decline when 
aged mice are exposed to the blood of young mice (Smith et al., 2015; Villeda et al., 
2014). In addressing the second question, we found that osteocalcin is also necessary for 
this beneficial effect of young blood, since cognitive improvements are not observed in 
the absence of osteocalcin. Importantly, when mouse recombinant osteocalcin is 
delivered peripherally to aged mice, it significantly reduces anxiety and improves 
memory, in part by increasing the expression and accumulation of a neurotropic factor 




To assess the influence of bone health on anxiety and cognition, we first asked 
what would be the consequence of a decrease in bone formation, because osteocalcin is 
synthesized by osteoblasts, the bone forming cells (Ferron et al., 2010). We analyzed 
mice lacking one allele of Runx2, a master regulator of osteoblast differentiation (Ducy et 
al., 1997) which is not detected in the brain, because these mice display reduced bone 
formation (Ducy et al., 1997; Lee et al., 1997) and have nearly a two-fold decrease in 
circulating levels of bioactive osteocalcin (Fig.1c, d). Consistent with less osteocalcin, 
expression of Gad1, a gene downregulated by osteocalcin signaling (Oury et al., 2013b), 
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was increased, whereas expression of Th, a gene up-regulated by osteocalcin signaling 
(Oury et al., 2013b), was decreased in Runx2+/- hippocampi. CREB phosphorylation, a 
biomarker of hippocampal-dependent memory formation (Gao et al., 2010; Kim et al., 
2014; Lakhina et al., 2015; Mayr and Montminy, 2001; Yiu et al., 2014), was also 
decreased in hippocampi of Runx2+/- mice. The same was true for BDNF, another 
marker of hippocampal-dependent memory formation (Anastasia et al., 2013; Hall et al., 
2000; Nagahara et al., 2009), whose putative regulation by osteocalcin was also 
previously unknown (Fig. 1e-g). Anxiety and exploratory-like behaviors were analyzed 
with the light-to-dark transition test, which is based on the innate aversion of rodents to 
brightly illuminated areas and their decreased spontaneous exploratory behavior in 
response to light (Crawley, 1985; David et al., 2009; Oury et al., 2013b; Vicente et al., 
2008; Zernig et al., 1992). Three-month-old Runx2+/- mice spent less time in the lit 
compartment than WT littermates (Fig. 1h). In the elevated plus maze test, anxiety results 
in a decrease in the proportion of time spent in the open arms. Runx2+/- mice spent less 
time in the open arms than WT littermates (Fig. 1h). These two tests indicate that haplo-
insufficiency at the Runx2 locus results in greater anxiety-like behavior. Of note, we 
observed the same behavior in Osteocalcin+/- mice, which have a similar decrease in 
circulating osteocalcin levels (Fig. 1d).  
Next, we assessed spatial learning and memory using two tests. In the Morris 
water maze test, Runx2+/- mice showed a significant delay in learning the location of the 
platform over 10 days compared to WT littermates (Fig. 1i). In the novel object 
recognition test (Denny et al., 2012; Ennaceur and Delacour, 1988; Oury et al., 2013b) 
which also evaluates hippocampal-dependent learning and memory (Broadbent et al., 
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2010; Denny et al., 2012; Oury et al., 2013b), Runx2+/- mice spent significantly less time 
exploring the novel object than their WT littermates (Fig. 1j). These results, which are 
similar to those observed in Osteocalcin+/- mice (Oury et al., 2013b), and are consistent 
with reports of decreased cognitive function in patients haplo-insufficient for Runx2 
(Izumi et al., 2006; Takenouchi et al., 2014), indicate that impaired bone formation 
hampers spatial learning and memory. 
Since osteocalcin becomes active as a hormone following its decarboxylation in 
the resorption lacuna (Ferron et al., 2010), we examined the influence of bone resorption 
on anxiety and cognition. Administration of alendronate, an inhibitor of bone resorption 
(Drake et al., 2008), for six weeks, effectively inhibited bone resorption and decreased 
circulating levels of bioactive osteocalcin, albeit to a lesser extent than in Runx2+/- mice 
(Fig. 1k, Supplementary Fig. 1 a-c). Alendronate-treated mice displayed an increase in 
anxiety-like behavior in the elevated plus maze test, and a delay in learning in both the 
Morris water maze and the novel object recognition tests. All these abnormalities were 
corrected by peripheral delivery of osteocalcin in alendronate-treated mice (Fig. 1l-n). 
Taken together, these experiments show that healthy bone remodeling reduces anxiety 
and enhances cognition, and that these beneficial effects are mediated in part by 
osteocalcin. 
In view of these results, we assessed whether variations in circulating osteocalcin 
levels contribute to the favorable effects of aerobic exercise on anxiety and cognition 
(Ding et al., 2006; van Praag et al., 2005). Because aerobic exercise results in a two-fold 
increase in the circulating levels of bioactive osteocalcin (Levinger et al., 2011; Mera et 
al., 2016), we subjected 3-month-old WT and Osteocalcin-/- mice to voluntary running 
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for 5 weeks to evaluate whether osteocalcin is a determinant of the beneficial influence of 
exercise on cognition. WT and Osteocalcin-/- mice ran comparable distances prior to 
behavioral analysis (Fig. 2a, b). Voluntary running significantly improved hippocampal 
memory in WT but not in Osteocalcin-/- mice (Fig. 2c). To examine how osteocalcin 
improves cognition during exercise, we performed a proteomic analysis on hippocampi of 
WT and Osteocalcin-/- mice at rest and after the period of voluntary running. This 
analysis revealed that after running there was a greater accumulation of proteins 
implicated in mitochondrial respiratory activity, protein translation, and 
cytoskeletal/vesicle trafficking in WT than in Osteocalcin-/- mice (Fig. 2d-f). Of note, 
Synaptotagmin III, a protein whose levels are increased in the hippocampi of WT but not 
Osteocalcin-/- mice after running, contributes to synaptic plasticity (Dean et al., 2009; 
Ding et al., 2006; Hilbush and Morgan, 1994; Li et al., 1995; Xi et al., 1999). Voluntary 
running also increased BDNF accumulation in hippocampi of WT but not of Osteocalcin-
/- mice, consistent with the notion that this protein may mediate some functions of 
osteocalcin in the brain (Fig. 2g). These results suggest that osteocalcin contributes to the 
beneficial effect of exercise on cognition and anxiety in young mice in part by regulating 
these pathways in the brain.  
In contrast, aging causes a decrease in cognition that can be reversed by supplying 
plasma from young WT mice to older WT mice (Villeda et al., 2014). Because 
circulating osteocalcin levels are 70% lower in older than in younger mice (Mera et al., 
2016), we asked whether the beneficial effect of plasma from young mice on the 
cognition and anxiety of older mice was due in part to their higher levels of osteocalcin 
(Supplementary Fig. 2a). To that effect, 16-month-old WT mice were injected with 
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plasma from either age-matched WT, from 3-month-old WT, or from 3-month-old 
Osteocalcin-/- mice (Fig. 2h). When subjected to the elevated plus maze test, 16-month-
old WT mice receiving plasma from 3-month-old WT mice were significantly less 
anxious than those receiving plasma from aged WT or from 3-month-old Osteocalcin-/- 
mice (Fig. 2i). Likewise, 16-month-old WT mice receiving plasma from 3-month-old WT 
mice displayed improved hippocampus-dependent memory as determined by the novel 
object recognition test. Again, such an improvement was not observed in mice receiving 
plasma from 3-month-old Osteocalcin-/- mice (Fig. 2j). To further demonstrate the 
contribution of osteocalcin to the benefit of receiving plasma from young mice, 16-
month-old WT mice were injected with plasma from Osteocalcin-/- mice that had been 
supplemented with mouse recombinant osteocalcin (90ng/g). This injection increased the 
circulating levels of osteocalcin (Supplementary Fig. 2b) and produced an improvement 
in anxiety and memory comparable to that resulting from the administration of young 
WT plasma (Figure 2i-j). Again, BDNF accumulation in the hippocampus was increased 
in 16-month-old WT mice receiving plasma from young WT mice, but not in those 
receiving plasma from aged WT or young Osteocalcin-/- mice (Fig. 2k). Taken together, 
these results indicate that the higher osteocalcin content in young blood contributes 
significantly to the beneficial effects of young plasma on cognition and anxiety in older 
mice. 
The decrease in cognition and in circulating osteocalcin levels observed in WT 
mice as they age, led us to ask whether exogenous osteocalcin would be sufficient to 
improve anxiety and cognition in aged WT mice. Because osteocalcin crosses the blood 
brain barrier (Oury et al., 2013b), we addressed this question by delivering vehicle or 
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osteocalcin (30 or 90ng/h) to 10- or 14-month-old WT mice peripherally for 60 days via 
mini-pumps prior to analyzing behavior (Supplementary fig. 3a). Using either the 
dark/light transition or the elevated plus maze test, we found that 12- and 16-month-old 
osteocalcin-treated WT mice showed significant improvement in exploratory behavior 
and decreased anxiety-like behavior compared to vehicle-treated littermates (Fig. 3a-b). 
Memory was also significantly improved in 12- and 16-month-old osteocalcin-treated 
mice compared to vehicle-treated littermates whether we used the Morris water maze or 
the novel object recognition tests (Fig. 3c-f). Lastly, we tested aged WT mice receiving 
osteocalcin for contextual fear conditioning, a form of associative memory that requires 
the integrity of the hippocampus (Fanselow and Poulos, 2005; Fioriti et al., 2015; 
LeDoux et al., 2000). Following training on day 1 using a 3-trial protocol, mice were 
tested for memory retention on day 2. Twelve- and 16-month-old osteocalcin-treated 
mice showed an increase in freezing time, suggesting better recall than vehicle-treated 
mice (Fig. 3g). The specificity of this osteocalcin-induced improvement in cognition was 
assessed using a mutant form of osteocalcin (Ocn-E13Q) (Lee et al., 2007) 
(Supplementary fig. 3b). Ocn-E13Q-treated WT mice did not display an improvement in 
anxiety and long-term memory compared to vehicle-treated littermates (Fig. 3a-f). These 
experiments demonstrate that when delivered peripherally, WT, but not mutant 
osteocalcin, decreases anxiety and improves memory in 12- and 16-month-old WT mice.  
The regulation of BDNF accumulation by osteocalcin observed in several of the 
mouse models tested led us to ask whether the influence of osteocalcin on behavioral 
functions in older mice may be caused in part by its regulation of BDNF expression 
and/or accumulation in the brain. To address this question, mice were injected 
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peripherally with WT or mutant osteocalcin (90ng/g) and hippocampi were analyzed 16 
hours later. We observed a significant increase in Bdnf expression in the hippocampi of 
mice receiving WT but not mutant osteocalcin. Accordingly, this injection of WT 
osteocalcin increased BDNF accumulation to the same extent as the positive control 
kainic acid (Rudge et al., 1998) in WT hippocampi (Fig. 3h-i). These results indicate that 




Radiobinding experiments on human tissue were done in collaboration with Dr. 
Victoria Arango, Dr. Mark Underwood, and Dr. J. John Mann, and Suham Kassir. The 
construct for Ocn-E13Q was made and generously provided by Dr. Stylianos Kosmidis. I 
thank Drs. Rae Silver and Joe LeSauter for sharing their animal facility and wheel 
running equipment with us, and Drs. Franck Oury and Mariana Ramos-Brossier for their 
collaboration on several molecular experiments.	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FIGURE 2: OSTEOCALCIN CONTRIBUTES TO THE INFLUENCE OF EXERCISE AND 
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FIGURE 3: EXOGENOUS OSTEOCALCIN CAN CORRECT INCREASED ANXIETY AND 
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SUPPLEMENTARY FIGURE 2: OSTEOCALCIN CONTRIBUTES TO THE INFLUENCE OF 
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SUPPLEMENTARY FIGURE 3: EXOGENOUS OSTEOCALCIN CAN CORRECT 
INCREASED ANXIETY AND IMPAIRED COGNITION IN AGED WT MICE	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Figure 1: Bone remodeling influences cognition through osteocalcin. 
 
(a-b) Total [3H]-osteocalcin binding and non-specific binding in the human amygdala (a) 
and hippocampus (b). The amygdala has homogeneous binding in all nuclei present at 
this level. In the hippocampus, the outline indicates the Granule Cell Layer of the Dentate 
Gyrus, which encompasses the hilar region and the CA3 region to which osteocalcin 
binds.  The lateral geniculate nucleus (LGN) and the tail of the Caudate Nucleus (CN) are 
indicated for reference. 
(c) Accumulation (Western blot) of Runx2 in various tissues of 3 month-old WT mouse. 
GAPDH was used as a loading control.  
(d) Circulating levels of bioactive osteocalcin in 3 month-old Runx2+/- (n=3) and WT 
(n=3) littermates.  
(e) Expression (qPCR) of Glutamate decarboxylase-1 (Gad 1), and Tyrosine hydroxylase 
(Th) in the brainstem and midbrain, respectively, of 3 month-old Runx2+/- (n=3) and WT 
(n=3) mice. Error bars represent SEM. The statistical test on the top of each graph 
represents the Student’s t test; p < 0.05 is significant. 
(f) Accumulation (Western blot) of brain-derived neurotrophic factor (BDNF) in 
hippocampi of 3 month-old Runx2+/- (n=3) and WT (n=3) mice. β-tubulin is used as a 
loading control. 
(g) (Left) Phospho-CREB (p-CREB) accumulation (Western blot) in the hippocampus of 
Runx2+/- (n=3) mice and WT (n=3) mice. CREB is used as a loading control. (Right) p-
CREB immunofluorescence in Runx2+/- (n=3) and WT (n=3) hippocampi. 
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(h) Dark to Light Transition (DLT) and Elevated Plus Maze (EPMT) tests performed in 
Runx2+/- (n=15) and WT mice (n=17), and Ocn+/- (n=27) and WT (n=34) mice. Time 
spent in the lit compartment and open arms was measured. 
(i) Morris water maze test (MWMT) performed over 10 days. The graphic shows the time 
(seconds) needed for each group of mice, Runx2+/- (n=15) and WT mice (n=16), to 
localize a submerged platform in the swimming area. Error bars represent SEM. The 
statistical test on the top of each graph represents the Student’s t test, (*) means p value 
of < 0.05 versus WT.  
(j) Novel object recognition (NOR) performed in Runx2+/- (n=7) and WT mice (n=10). 
Preference index (time spent with novel object/total exploration time) was measured. 
(k) Schematic representation of the timeframe of alendronate and osteocalcin 
administration followed by behavioral testing. 
(l) EPMT performed in vehicle-treated (n=9), alendronate-treated (n=9), and alendronate 
+ osteocalcin-treated (n=9) WT mice. Number of entries and time spent (sec) in the open 
arms were scored. 
(m) MWMT performed over 10 days. The graphic shows the time (seconds) needed for 
each group of mice, vehicle-treated (n=8), alendronate-treated (n=12), and alendronate + 
osteocalcin-treated (n=11), WT mice to localize a submerged platform in the swimming 
area. Error bars represent SEM. The statistical test on the top of each graph represents the 
Student’s t test, (*) means p value of < 0.05 versus vehicle-treated. 
(n) NOR performed in vehicle-treated (n=7), alendronate-treated (n=8), and alendronate 
+ osteocalcin-treated (n=8) WT mice. Preference index (time spent with novel 
object/total exploration time) was measured. 
	  
	   80	  
 
Figure 2: Osteocalcin contributes to the influence of exercise and aging on cognition 
and anxiety. 
 
(a) Schematic representation of the voluntary wheel running or resting experiment.  
(b) Total number of wheel revolutions made by 4 month-old Ocn-/- (n=11) and WT 
(n=11) control mice over a 5 week voluntary running period, ns: non-significant. 
(c) NOR performed in Ocn-/- and WT mice. Preference index (time spent with novel 
object/total exploration time) running/resting was measured for each group (n=12 per 
group). 
(d) Proteins involved in energy metabolism and cellular respiration that are significantly 
increased after running in the hippocampus of WT but not Ocn-/- mice (n=3 per group). 
(e) Proteins involved in vesicle trafficking and synaptic plasticity that are significantly 
increased after running in the hippocampus of WT but not Ocn-/- mice (n=3 per group). 
(f) Proteins involved in protein translation that are significantly increased after running in 
the hippocampus of WT but not Ocn-/- mice (n=3 per group). 
(g) BDNF accumulation (Western blot) in hippocampi of 4 month-old running or resting 
Ocn-/- and WT control mice (n=5 per group). β -tubulin is used as a loading control. 
(h) Schematic representation of the plasma administration by tail vein injection in aged 
mice experiment. 
(i) BDNF accumulation (Western blot) in hippocampi of aged mice receiving plasma 
from aged, young WT or young Ocn-/- mice (n=3 per group). β -tubulin is used as a 
loading control. 
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(j) EPMT performed in aged mice receiving plasma from aged (n=7), young WT (n=13), 
or young Ocn-/- mice (n=10), and aged mice receiving plasma from young Ocn-/- 
supplemented with 90ng/g osteocalcin (n=9). Number of entries and time spent (Sec) in 
the open arms were scored. The statistical test on the top of each graph represents the 
Student’s t test, (*) means p value of < 0.05 versus aged-aged. 
(k) NOR performed in aged mice receiving plasma from aged (n=7), young WT (n=13), 
or young Ocn-/- mice (n=10), and aged mice receiving plasma from young Ocn-/- 
supplemented with 90ng/g osteocalcin (n=9). Preference index (time spent with novel 
object/total exploration time) was measured for each group. The statistical test on the top 
of each graph represents the Student’s t test, (*) means p value of < 0.05 versus aged-
aged. 
 
Figure 3: Exogenous osteocalcin improves anxiety and cognition in aged WT mice. 
 
(a) and (b) DLT and EPMT performed in  12 and 16 month-old WT mice treated with 
vehicle, WT osteocalcin (n=13) or OcnE13Q (n=8). Time spent in the lit compartment 
and open arms was measured. 
(c-e) MWMT performed over 10 days. The graphic shows the time (seconds) needed for 
each group of mice, WT osteocalcin (n=14) or OcnE13Q (n=8), to localize a submerged 
platform in the swimming area. Error bars represent SEM. The statistical test on the top 
of each graph represents the Student’s t test, (*) means p value of < 0.05 versus vehicle-
treated. 
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(f) NOR performed in12 and 16 month old WT mice treated with vehicle, WT 
osteocalcin treated (n=13), or OcnE13Q (n=8). Preference index (time spent with novel 
object/total exploration time) was measured for each group. 
(g) Contextual fear conditioning (CFC) performed in vehicle- or osteocalcin-treated 12 
and 16 month-old WT mice (n=14). Percent freezing 24 hours after training was 
measured.  
(h) Bdnf expression (qPCR) in the hippocampus of WT mice injected peripherally with 
vehicle (n=4), osteocalcin (n=4) or osteocalcin-E13Q (n=3). Error bars represent SEM. 
The statistical test on the top of each graph represents the Student’s t test. 
(i) BDNF accumulation (Western blot) in the hippocampus of WT mice injected 
peripherally with vehicle (n=3), kainic acid as a positive control (n=3), or osteocalcin 
(n=3). β-tubulin is used as a loading control. 
 
Supplementary figure 1: Bone remodeling influences cognition through osteocalcin. 
 
(a) Bone volume/trabecular volume in vehicle-treated (n=7), alendronate-treated (n=8), 
and alendronate + osteocalcin-treated (n=8) WT mice. Error bars represent SEM. (*) 
means p value of < 0.05; p < 0.05 is significant. 
(b) Circulating levels of carboxy-terminal collagen crosslinks (CTX) in vehicle-treated 
(n=10) or alendronate-treated (n=13) mice. Error bars represent SEM. (*) means p value 
of < 0.05. 
(c) Circulating levels of bioactive osteocalcin in vehicle-treated (n=8) or alendronate-
treated (n=13) mice. Error bars represent SEM. (*) means p value of < 0.05. 
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Supplementary figure 2: Osteocalcin contributes to the influence of exercise and 
aging on cognition and anxiety. 
 
(a) Bioactive osteocalcin content in plasma pooled from young WT (n=9), young Ocn-/- 
(n=9) or aged WT (n=5) mice used for the treatment of aged mice (Fig. 2).  
(b) Bioactive osteocalcin content in the serum of aged mice (n=4, paired group 
comparison) 24 hours before or 10 minutes after injection with plasma from young Ocn-
/- supplemented with 90ng/g osteocalcin. 
 
Supplementary figure 3: Exogenous osteocalcin improves anxiety and cognition in 
aged WT mice. 
 
(a) Bioactive osteocalcin content in the serum of 16 month-old mice (n=8) before and 
after peripheral osteocalcin treatment (90ng/hr) via osmotic minipump (Alzet) 
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Part III. Initiating the search for a receptor mediating osteocalcin’s 
signal in the hippocampus and other parts of the brain.  
 
By highlighting the importance of osteocalcin in the regulation of anxiety and 
cognitive functions in aged mice, the body of data I have generated during my graduate 
work raised the question of the signaling pathway used by this hormone in the brain. The 
bell-shaped curve of osteocalcin signaling in neurons (Oury et al., 2013b) suggested that 
like Gprc6a, its receptor in peripheral tissues,  osteocalcin’s receptor in the brain might be 
a GPCR. Therefore, we searched for an orphan GPCR that 1] would belong, like Gprc6a, 
to the class C family of GPCRs (Chun et al., 2012); 2] would be expressed in the 
midbrain and hippocampus, and 3] would not be expressed in any cell type where Gprc6a 
is expressed. Our laboratory used two independent approaches to identify a candidate 
GPCR. The first approach was to carefully re-examine the results of a screen using the 
TANGO assay (Kroeze et al., 2015), which my mentor’s laboratory had performed in 
2011 to test all human orphan GPCRs in search of those that would mediate osteocalcin’s 
signal in Leydig cells of the testis (Figure e). Besides Gprc6a, which is expressed in 
Leydig cells, this screen identified another GPCR that was not expressed in Leydig cells 
(Oury et al., 2011), but was consistently responsive to osteocalcin: Gpr158.  
The second approach was a RNA-Seq analysis that I performed on dissociated 
embryonic mouse hindbrain neurons treated with osteocalcin or vehicle. I used this 
strategy because I had previously shown that these neurons are responsive to osteocalcin 
treatment in cell culture with changes in expression of Tph2 and Gad1 (Oury et al., 
2013b).  This RNA-Seq analysis revealed expression of Gpr158 in osteocalcin-binding 
primary neurons (Figure b).  
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In view of these encouraging results, we conducted a systematic analysis of the 
expression pattern in the brain and peripheral organs of all orphan class C GPCRs and 
identified Gpr158 as being the only one that is expressed in the ventral tegmental area 
and the CA3 region of the hippocampus, where osteocalcin has been previously shown to 
bind. Unlike other orphan class C family Gpcrs, it is not expressed in peripheral tissues 
where osteocalcin signals in a Gprc6a-dependent manner (Figure c-g). Gpr158 is also 
expressed in the somatosensory, motor and auditory area of the cortex, the piriform 
cortex and the retrosplenial area (Fig 3e). It will be important in future experiments to 
determine the role of osteocalcin signaling in these various areas of the brain. Currently, 
the postdoctoral fellow in the Karsenty lab, Arnaud Obri with whom I have collaborated 
on this latter part of my work, is generating Gpr158 global and conditional knockout 
mice, to test the effect of the deletion of this receptor with regard to the behavioral 
phenotypes observed in Ocn-/- mice. 
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Figures 
FIGURE 1: IDENTIFICATION OF A PUTATIVE RECEPTOR FOR OSTEOCALCIN IN THE 
BRAIN 































































































































































































































































	   87	  
	  
Figure 1: Identification of a putative receptor for osteocalcin in the brain 
(a) TANGO assay utilizing Hek293T cells transfected with various orphan human 
GPCRs 
(b) RNAseq of primary e14.5 hindbrain neurons binding osteocalcin, showing expression 
of various orphan GPCRs 
 
(c-d) in situ hybridization showing gpr158 expression in TH positive neurons of the VTA 
and in the EC and hippocampus 
 
(e-g) Expression (qPCR) of orphan GPCRs in muscle, testis and adipocytes  
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Chapter 3. Discussion 
 
Taken as a whole, the work I have performed as a graduate student provides 
evidence that the bone-derived hormone osteocalcin affects brain development and 
functions. After birth, osteocalcin favors neurotransmitter synthesis, prevents anxiety- 
and depression-like behaviors and enhances spatial learning and memory. Recent clinical 
associative studies suggest the same is true in humans (Bradburn et al., 2016). During 
embryonic development, maternal osteocalcin crosses the placenta and prevents neuronal 
apoptosis in the hippocampus. This latter pool of osteocalcin is also required for optimal 
spatial learning and memory in the adult offspring. These results undoubtedly broaden 
the spectrum of functions of the skeleton, provide a molecular basis for the long-observed 
maternal influence on fetal brain development, and potentially shed new light on a 
potential cause of the decrease of cognitive functions with aging. 
That a high serotonin content in the brain results in a high bone mass despite 
hypogonadism (Ducy et al., 2000a; Yadav et al., 2009) illustrates how powerful the 
central control of bone mass is. At the same time, this body of work implied that bone, in 
a feedback loop, might influence the development and functions of the brain. To 
experimentally explore this hypothesis, we focused on osteocalcin because of the obvious 
passivity of the Ocn-/- mice that was not due to any metabolic causes. The analysis I have 
conducted has revealed that osteocalcin favors the expression of genes necessary for the 
synthesis of all monoamine neurotransmitters (serotonin, catecholamines) and inhibits the 
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expression of genes needed for GABA synthesis. As a result, the contents of serotonin, 
dopamine and norepinephrine are low while that of GABA is high in the brains of Ocn-/- 
mice. Of note, the decrease in norepinephrine content observed in the brains of Ocn-/- 
mice may explain the high bone phenotype originally noted in the Ocn-/- mice (Ducy et 
al., 1996). More recently, as presented in Part II of the previous chapter, our work 
showed that osteocalcin also regulates the expression of Bdnf. 
Several observations indicate that osteocalcin signals directly in the brain. The 
first is that this hormone, preferably when uncarboxylated, crosses the blood-brain barrier 
and binds specifically to neurons of the brainstem, midbrain and hippocampus. Of note, 
the carboxylated form of the hormone does not cross the blood-brain barrier nearly as 
efficiently. Second, osteocalcin favors the expression of genes necessary for serotonin 
and catecholamine synthesis and on the other hand inhibits expression of genes involved 
in GABA biosynthesis. Third, treatment of primary hindbrain neurons with recombinant 
mouse osteocalcin affects calcium flux and the firing rate of various neurons and 
interneurons of the brainstem. Fourth and more directly, intracerebroventricular delivery 
of osteocalcin at a dose that does not cross the blood-brain barrier normalizes gene 
expression and corrects all behavioral abnormalities observed in Ocn-/- mice (Oury et al., 
2013b).   
A consequence of osteocalcin’s regulation of neurotransmitter synthesis is that 
this hormone influences behavior. Indeed in the mouse, osteocalcin prevents anxiety and 
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depression. The deleterious effect of a post-natal and osteoblast-specific Ocn inactivation 
on anxiety and depression provide two additional pieces of evidence that bone-derived 
signals act in the brain post-natally to affect behavior. Osteocalcin also favors spatial 
learning and memory as determined by the Morris Water Maze test that is thought to 
reflect, at least in part, functions of the hippocampus (Morris et al., 1982). Additional 
tests more selectively assessing hippocampal-dependent learning such as novel object 
recognition and contextual fear conditioning, verified that the deficit in spatial learning 
and memory in Ocn-/- mice could be traced back to the hippocampus. Those observations 
are consistent with the fact that the dentate gyrus area is smaller and that neuronal 
survival and adult neurogenesis in the hippocampus are decreased in Ocn-/- mice (Oury 
et al., 2013b).  
Ocn is one of the latest genes to be expressed during skeletogenesis; therefore, it 
was expected that this hormone would not exert any significant functions during 
development. Surprisingly, however, our analysis has shown that the maternal pool of 
this hormone crosses the placenta, is needed for fetal brain development and thereby 
affects spatial learning and memory in the adult offspring. Indeed, osteocalcin is detected 
in the blood of embryos 2 days before they begin to express Ocn and measurements of 
circulating levels of this hormone in WT or Ocn-/- embryos carried by either WT or 
Ocn+/- mothers showed that the majority of osteocalcin present in the circulation of 
embryos originates from the mother. Even more objectively, a thorough histological 
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analysis of the brains of Ocn-/- embryos carried by either Ocn-/- or Ocn+/- mothers 
showed that maternally-derived osteocalcin is needed to prevent neuronal apoptosis, in 
the hippocampus if not elsewhere in the brain. The undercarboxylated form of 
osteocalcin, the one that crosses the placenta most efficiently, adds additional support to 
the notion established in the laboratory for other aspects of osteocalcin biology, that the 
active form of osteocalcin is the undercarboxylated one (Lee et al., 2007; Ferron et al., 
2010). 
By affecting fetal brain development, maternally-derived osteocalcin also favors 
behavior in the adult offspring, since providing this hormone to Ocn-/- mothers during 
their pregnancies rescued the spatial learning and memory deficits in their adult Ocn-/- 
progeny. It also improved, albeit modestly, some parameters of anxiety in these 
progenies. In view of these results, it is tempting to speculate that mediocre bone health 
in the mother, leading to a decrease in osteocalcin synthesis and/or activation by bone 
resorption, could be a contributing factor to the high incidence of neuropsychiatric 
diseases in the children of women undernourished during pregnancy, since under-
nutrition hampers bone remodeling (Seibel, 2002). This hypothesis has important 
biomedical implications, which I have begun to test in the mouse in the second part of my 
graduate work.  
There is often a decrease in bone mass and a mild to severe cognitive impairment 
that in turn favors falls and bone fractures in the elderly (Hsu et al., 2012). Hence, a 
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vicious cycle develops between the decrease in bone mass and the decline in cognitive 
functions during aging. In that regard, our results may be important in two respects. First, 
they raise the prospect that a decrease in bone mass, as seen during aging, may be an 
unanticipated cause of the decrease in cognitive functions seen in the older population 
because of a decrease in the synthesis and/or activation of osteocalcin. Therefore, they 
suggest that improving bone health during aging may have beneficial effects on 
cognition. In broader terms, the fact that osteocalcin favors functions such glucose 
homeostasis, male fertility and cognitive functions that deteriorate with age, raises the 
testable hypothesis that bone, through its endocrine function, may be a gatekeeper, if not 
a determinant, of organismal aging. Work carried out in the Karsenty laboratory is 
currently testing this hypothesis. 
The second set of studies that I performed directly addressed some of these 
notions. Observations of skeletal dysplasias, such as cleidocranial dysplasia, which affect 
cognition, raise questions about the molecular link between neural and skeletal biology. 
In addressing this first notion, we found that impairment in either bone formation or bone 
resorption negatively impacts both anxiety and memory. Specifically, Runx2+/- mice, 
which have low bone formation, and consequently, low circulating bioactive osteocalcin 
levels, have increased anxiety and mediocre memory when each parameter was examined 
by two independent tests. On the other hand, when we treated mice with alendronate, a 
small molecule inhibitor that is widely used in the treatment of osteoporosis to block 
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bone resorption, WT mice also developed impairments in anxiety and memory, and these 
deficits were rescued by exogenous peripheral delivery of osteocalcin. Next, we asked 
whether osteocalcin is involved in cognitive improvement after exercise. We found that 
in the absence of osteocalcin, mice are unable to improve cognitive functions after 5 
weeks of voluntary exercise, thus suggesting that this hormone is needed for the well-
characterized improvement in cognition seen with exercise.  
Recent studies have shown a reversal in age-related cognitive decline when aged 
mice are exposed to the blood of young mice (Smith et al., 2015; Villeda et al., 2014). In 
addressing the notion that aging bones may directly contribute to an aging brain, we also 
found that osteocalcin is necessary for this beneficial effect of young blood, since 
cognitive improvements are not observed when using plasma obtained from young Ocn-/- 
mice. Finally, and perhaps most importantly, when mouse recombinant osteocalcin is 
delivered peripherally to aged mice, it reduces anxiety and improves memory, in part by 
increasing BDNF levels in the hippocampus.  
Collectively, these studies have shown that the skeleton via osteocalcin is a potent 
regulator of cognition in bony vertebrates. Besides the basic science questions raised by 
these findings, it is clear that in the face of an aging population, it becomes even more 
important for future studies to determine whether osteocalcin may act therapeutically in 
humans to treat the growing epidemic of cognitive decline that accompanies aging. 
Additionally, it would be of great importance to dissect and fully characterize the 
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A second receptor for osteocalcin 
The existence of substantial metabolic abnormalities in Ocn-/- mice was an 
important concern during these studies and a potential confounding factor for the 
interpretation of the results.  While I cannot formally rule out that these metabolic 
abnormalities may contribute to the behavioral phenotypes of the Ocn-/- mice, I should 
note that mice lacking Gprc6a, the only known receptor for osteocalcin, are 
indistinguishable from Ocn-/- mice in terms of energy metabolism, and yet do not present 
any of the molecular and behavioral defects seen in absence of Ocn. This is consistent 
with the observation that despite numerous attempts using different techniques, we failed 
to detect Gprc6a expression in areas of the brain where osteocalcin signals. This 
observation suggests that as it is the case for other hormones and neuromodulators, 
osteocalcin uses several receptors to fulfill all its known functions.  Hence, our findings 
raise the question of the molecular mechanisms used by this hormone in the brain. 
Addressing this question on both molecular and genetic grounds is now a priority if we 
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want to understand the entire spectrum of functions of osteocalcin in the brain, and its 
specific effects on different neuron types and sub-regions of the brain.  
The functions previously ascribed to osteocalcin by our laboratory include the 
regulation of insulin secretion and glucose homeostasis, testosterone synthesis by the 
Leydig cells of the testes and male fertility, and the regulation of neurotransmitter 
synthesis and cognitive functions (Karsenty and Ferron, 2012; Karsenty and Oury, 2012; 
Lee et al., 2007; Oury et al., 2013b; Oury et al., 2011). Gene expression analysis and cell-
specific gene deletion experiments in the mouse have established that Gprc6a is the 
receptor mediating osteocalcin’s regulation of insulin expression in pancreatic β cells, of 
testosterone synthesis in Leydig cells of the testis (Karsenty and Ferron, 2012; Karsenty 
and Oury, 2012; Wei et al., 2014), and of muscle function mediated by myofibers (Mera 
et al., 2016). Yet, several lines of evidence indicate that Gprc6a does not mediate 
osteocalcin’s functions in the brain: 1) Gprc6a expression cannot be detected in regions 
of the brain where osteocalcin signals, 2) the expression of Tph2, Th, Gad1 and Gad2, 
which are the biosynthetic enzymes responsible for the production of serotonin, 
dopamine, and GABA, respectively (Tochitani and Kondo, 2013; Walther et al., 2003; 
Wang et al., 2011), as well as the accumulation of these monoamine neurotransmitters 
and GABA, are normal in Gprc6a-/- mice, and 3) Gprc6a-/- mice do not display any of 
the cognitive abnormalities seen in Ocn-/- mice (Oury et al., 2013b).  All these data 
concur to indicate that osteocalcin signals through a different receptor in the brain to 
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regulate neurotransmitter synthesis and cognitive function and necessitate the 
identification of this receptor. 
The criteria that guided us in the search for this putative receptor were that it 
should: a) be expressed in the brainstem, midbrain, and hippocampus where osteocalcin 
signals, b) be responsive to osteocalcin in vitro, and c) belong to the same subfamily of 
GPCRs as Gprc6a.  
We used two independent approaches to identify a candidate GPCR. The first 
approach was to carefully re-examine the results of a screen using the TANGO assay 
(Kroeze et al., 2015), which our laboratory had previously performed to test all human 
orphan GPCRs in search of those that would mediate osteocalcin’s signal in Leydig cells 
of the testis. Besides Gprc6a, which is expressed in Leydig cells, this screen identified 
another GPCR that was not expressed in Leydig cells (Oury et al., 2011), but was 
consistently responsive to osteocalcin: Gpr158.  
The second approach was a RNA-Seq analysis performed on dissociated 
embryonic mouse hindbrain neurons treated with osteocalcin or vehicle, which I had 
previously found to be responsive to osteocalcin treatment in cell culture with changes in 
expression of Tph2 and Gad1 (Oury et al., 2013b). Importantly for our purpose, Gpr158 
was robustly expressed in osteocalcin-binding cells. Two other features of Gpr158 
suggest that it might be an osteocalcin receptor in the brain. First, and in situ 
hybridization analysis and multiple qPCR experiments have shown that Gpr158 is 
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expressed in the brainstem, the ventral tegmental area of the midbrain, and the 
hippocampus where osteocalcin signals. In contrast, Gpr158 is not expressed in the 
peripheral organs where osteocalcin signals through Gprc6a. Second, Gpr158 is the only 
candidate GPCR identified through this assay that belongs to the same family as Gprc6a. 
This is an important point, since historically, when a ligand can signal through several 
GPCRs, these GPCRs belong to the same subfamily (van der Horst et al., 2010).  Third, 
when our collaborator, Dr. Franck Oury, delivered shRNA by ICV to inactivate Gpr158 
in the brain, he observed that while mice receiving scramble control shRNA improve in 
the NOR and CFC paradigms upon the central delivery of osteocalcin, those receiving the 
Gpr158-shRNA failed to show any cognitive improvements on these tests (Oury et al., 
personal communication).  
Taken together, these preliminary data call for a systematic and in-depth analysis 
of Gpr158’s functions in the brain. A postdoctoral fellow in the laboratory, Arnaud Obri, 
is currently analyzing Gpr158 null mice to determine whether they phenocopy Ocn-/- 
mice.  He is also generating mice to determine whether Gpr158 mediates osteocalcin 
signal in the hippocampus and in serotonergic neurons, where osteocalcin signals.  
To determine whether Gpr158 regulates hippocampal development and/or 
cognitive functions, it may be appropriate to generate Gpr158fl/fl mice harboring 2 
different Cre driver mouse lines: the Grik4-Cre mice (Nakazawa et al., 2002) to delete 
Gpr158 in the CA3 region of the hippocampus, and the ePet-Cre mice (Scott et al., 2005) 
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to delete Gpr158 in serotonergic neurons, provided of course these cre-mice delete gene 
only in the cells of interest. The mutant mice will then be subjected to all molecular and 
behavioral assays that we have used to characterize the Ocn-/- mice to determine which 
brain regions and neuron types are responsible for receiving osteocalcin signaling in the 
brain.  
At this time, I cannot predict which specific behavioral abnormalities will be 
observed in ePet-cre; Gpr158fl/fl, or Grik4-cre; Gpr158fl/fl mice. However, if, as our 
preliminary data suggests, Gpr158 is a receptor for osteocalcin in the brain, if osteocalcin 
acts directly on serotonergic neurons, I expect that the ePet-cre; Gpr158fl/fl mice may 
have decreased Tph2 expression and serotonin content. Likewise, Grik4-cre; Gpr158fl/fl 
mice, which will lack Gpr158 in the CA3 region of the hippocampus, may have defects 
in long-term memory, a function controlled by the hippocampus9. The severity of the 
phenotype presented for each mutant strain should help narrow down the regions of the 
brain or the specific neuronal populations that are able to respond to osteocalcin to 
regulate neurotransmitter content, mood, and behavior. A second possibility is that 
Gpr158-/- mice will have a milder phenotype than Ocn-/- mice, indicating the existence 
of a third receptor for osteocalcin in the brain that must also be identified.  
A third possible outcome is that mice lacking Gp158 in various parts of the brain 
will not harbor any abnormalities in gene expression and behavior even if the global 
knockout of Gpr158 do present with these phenotypes. This would not rule out that 
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Gpr158 is a receptor for osteocalcin in the respective brain regions expressing each cre, 
but would suggest that exogenous osteocalcin has the ability to activate an additional 
receptor, which could compensate for the lack of signal transduced by Gpr158 in those 
regions. This would also lead to a search for an additional osteocalcin brain receptor. If 
this situation arises, it may be beneficial to re-examine the data produced by the RNAseq 
and the TANGO assay to identify novel GPCR candidates to be tested as potential 
osteocalcin receptors.  
In addition to being expressed in the ventral tegmental area of the midbrain, 
hindbrain, and the CA3 region of the hippocampus, the in situ hybridization we have 
conducted has revealed that Gpr158 is expressed in several cortical areas where the 
function of osteocalcin has not been demonstrated. This suggests that if Gpr158 is indeed 
a receptor for osteocalcin in the brain, osteocalcin may also signal in these regions of the 
brain where its functions are unknown. Again, it will be important to explore these 
functions by generating mice specifically lacking Gpr158 in these regions. Moreover, the 
use of hippocampal neurons in culture can be used to dissect the mechanism by which 
osteocalcin transduces its signal. For example, cells in culture can be treated with 
osteocalcin, and second messengers such as cAMP, IP3; DAG; Ca2+, can be measured to 
determine which signal transduction systems are altered upon osteocalcin treatment. 
Once this readout is determined, Gpr158-/- hippocampal cells can be used to confirm that 
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this system cannot be activated in the absence of osteocalcin’s putative receptor in 
neurons.  
 
Osteocalcin and the age-related decline in cognitive functions 
In my view, the most important implication of this work is the suggestion that 
perhaps osteocalcin can be used therapeutically to treat age-related cognitive decline in 
humans, as it does in mice. There are many steps required to test this notion. Specifically, 
in phase I, clinical trials using healthy individuals must be conducted to determine the 
drug’s basic properties and safety profile in humans. In phase II, efficacy trials begin as 
the drug is administered to volunteers of the target population. In phase III, safety, 
efficacy and side effects are measured. If osteocalcin can improve cognitive functions in 
healthy aging adults with minimal or no side effects, then there will be great potential to 
establish collaborations to develop osteocalcin into a medication that can be accessed by 
our growing aging population.  
If indeed osteocalcin has the ability to reverse even in part symptoms of the aging 
brain, further clinical trials both on mice and in humans can be designed to determine 
whether osteocalcin can also have therapeutic effects for Alzheimer’s disease. 
Alzheimer’s disease is characterized initially by a mild decline in cognitive function that 
is followed by deficits in multiple cortical functions at later stages. Many mouse models 
mimicking some or most aspects of the disease exist, and one that is widely used by the 
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community of researchers in the field at Columbia University Medical Center is the 
transgenic mouse carrying both the mutant amyloid precursor protein (APP) and 
presinilin-1 (PSI) (APP/PSI mice) (Jankowsky et al., 2007; Minkeviciene et al., 2009; 
Shen et al., 1997). These mutant mice reproduce the cognitive deficits that occur in 
Alzheimer patients. Specifically, they have impaired LTP, spatial working memory, and 
contextual learning around 3 to 4 months of age. Experiments can be performed at two 
distinct ages in this mouse model to determine whether osteocalcin can 1) be preventative 
against the Alzheimer’s disease-like symptoms in these mice, and 2) whether osteocalcin 
can reverse symptoms that have already begun to manifest.  
In the first experiment, we could ask if the peripheral delivery of exogenous 
osteocalcin can prevent or at least postpone the appearance of amyloid plaques in 
APP/PSI mice that are 8 weeks of age, prior to the onset of symptoms. Following 
osteocalcin infusion, we would harvest brains and quantify the number of amyloid 
plaques in APP/PSI mice infused with osteocalcin in comparison to those infused with 
vehicle using Congo red staining (Wilcock et al., 2006) and immunohistochemistry by an 
anti-beta-amyloid antibody (Hartman et al., 2005). 
In the second experiment, one could ask instead if the central delivery of 
exogenous osteocalcin can rescue, at least partially, the histological defects and 
behavioral phenotypes in APP/PSI mice once they are already present. To that end, one 
would start the osteocalcin peripheral infusion either at 3, 4 or 5 months of age and 
analyze mice one month later. Fist, one could perform a battery of behavioral tasks: 
Anxiety-like behavior could be analyzed by the dark/light transition test, the elevated 
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maze test (Holmes et al., 2000; Lira et al., 2003), and the open field test (David et al., 
2009; Sahay et al., 2011). Spatial learning and memory will be assayed through the 
Morris water maze task (Morris et al., 1982), contextual fear conditioning (Denny et al., 
2012), and novel object recognition (Denny et al., 2012). Second, to determine whether 
osteocalcin can rescue the histological impairments observed in the APP/PSI mice, at the 
end of the behavioral analysis, brains could be harvested and the number of amyloid 
plaques quantified as previously described. 
Currently, I can foresee three possible outcomes to these proposed experiments. 
The first is that osteocalcin infusion will prevent the appearance, and rescue, even if only 
partially, the manifestations of Alzheimer’s disease in the APP/PSI mice. This obviously 
would be the most significant outcome as it would immediately identify osteocalcin as a 
potential drug for the treatment of this disease. The second possible outcome is that 
osteocalcin infusions will postpone the appearance of amyloid plaques but will not rescue 
the phenotype once it is fully present. The third, more negative, outcome would be that 
osteocalcin infusions would not prevent, postpone, or revert the phenotype of APP/PSI 
transgenic mice. For now, it is impossible to determine which outcome is the most likely, 
but these experiments are needed to evaluate the therapeutic potential of osteocalcin in 
treating Alzheimer’s disease. 
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Chapter 4. Methods 
 
Behavioral studies 
Animals and sample size: 
All animals of the same batch were born within an interval of 2 weeks and were 
kept in mixed genotype per groups of 5 females in the same cage, at standard laboratory 
conditions (12 h dark/light cycle, constant room temperature and humidity, and standard 
lab chow and water ad libitum). All the tests described below were performed between 11 
A.M. and 5 P.M. For each test, the mice were transported a short distance from the 
holding mouse facility to the testing room in their home cages or in the transport boxes 
filled with wooden bedding from their home cages.  
All mice were maintained on a pure 129SV/EV genetic background except the 
inducible deletion Ocn model (OcnosbERT2) which was mixed background: 25% C57/BL6 
and 75% 129sv/ev, and Runx2+/- mice which have been previously described (Ducy et 
al., 1996; Ducy et al., 1997) were maintained on a C57/BL6 background. For all 
experiments, we used littermates as controls. Females were used in all experiments unless 
otherwise stated. Osmotic pumps, plasma injection and alendronate injection experiments 
were performed in 12-, 16-, and 3-month-old 129S6/SvEvTac mice obtained from 
Taconic Biosciences. For inducible gene deletion, tamoxifen was prepared in corn oil, 
and injected daily intraperitoneally (IP) (1 mg/20g of body weight) for 7 days. Controls 
for the inducible inactivation of Ocn were a1Col1-Cre, Ocnflox/flox and WT mice.  
For plasma injection experiments, 100 µl of plasma were injected 8 times during 
24 days, via tail vein. For osteocalcin delivery in WT mice, pumps (Alzet micro-osmotic 
pump, Model 1002) delivering osteocalcin (30 ng/hr for 12 month-old and 90ng/hr for 16 
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month-old mice), or vehicle, were surgically installed subcutaneously in the back of 
mice. Each group described is represented individually in each panel. For alendronate 
delivery to 3 month-old mice, intraperitoneal injections (40 mg/kg) were performed twice 
a week for 6 weeks. During the last 4 weeks of treatment and during behavioral testing, 
half of the alendronate-treated mice received 90 ng/hr osteocalcin by osmotic pump.  
Control mice receiving vehicle or mice receiving alendronate were implanted with 
osmotic pumps delivering vehicle only. 
Longitudinal testing of the mice was performed on an extended battery of 
functional tests between 3 and 4 month-of age, and mice weight was between 22g and 
28g. All experiments involving animals were approved by the Institutional Animal Care 
and Use Committee of Columbia University Medical Center. Behavioral tests were 
performed on n ≥ 2 independent mice cohorts including n ≥ 7 mice per group. 
 
Tail suspension test (TST) (Mayorga et al., 2001; Steru et al., 1985). Mice were 
transported a short distance from the holding facility to the testing room in their home 
cages and left there undisturbed for at least one hour. Each mouse was suspended by its 
tail 35 cm above the floor using adhesive tape (distance from tip of tail was 2 cm). 
Typically, mice demonstrated several escape-oriented behaviors interspersed with 
temporally increasing bouts of immobility. The parameter recorded was the number of 
seconds spent immobile. Mice were scored over a 5 min period, blind to the genotype of 
the mice. 
 
Open field paradigm test (OF) (David et al., 2009). Mice were transported a short 
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distance from the holding facility to the testing room in their home cages and left there 
undisturbed for at least 30 min. Each animal was placed in a 43 × 43 cm open field 
chamber, and tested for 30 min. Mice were monitored throughout each test session by 
video tracking and analyzed using Matlab software. Mice were placed individually into 
the center of the open-field arena and allowed to explore freely. The overall motor 
activity was quantified as the total distance travelled. Anxiety was quantified by 
measuring the number of rearings, and the percentage of the time and distance spent in 
the center versus periphery of the open field chamber.  
 
Elevated plus maze test (EPM). Mice were transported a short distance from the 
holding facility to the testing room in their home cages and left there undisturbed for at 
least 1 hour. The EPM was made of opaque plastic and consisted of four arms measuring 
each 7.6 cm in width and 35 cm in length, elevated 31cm above the floor. Two arms were 
enclosed by 15 cm high walls, the other two were open. Each mouse was placed in the 
center of the maze and allowed to explore the apparatus for 5 min. Global activity was 
assessed by the number of entries in the open arms (David et al., 2009) scored by an 
experimenter blind to the genotype of the mice. Anxiety was assessed by the time spent 
in the open arms. 
 
Mouse forced swim test (FST) (David et al., 2009). Mice were transported a short 
distance from the holding facility to the testing room in their home cages and left there 
undisturbed for at least 30 min. Mice were placed individually into glass cylinders 
(height: 25 cm, diameter: 10 cm) containing 10 cm high water, maintained at 23–25 °C. 
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Briefly, mice were dropped individually into glass cylinders (height: 25 cm, diameter: 
10 cm) containing 18 cm water height, maintained at 23-25 °C. Animals were tested for a 
total of 6 min. The total duration of immobility time was recorded manually. Mice were 
considered immobile when they made no attempts to escape with the exception of the 
movements necessary to keep their heads above the water. The total duration of 
immobility was recorded. Mice were considered immobile when they made no attempts 
to escape with the exception of movements necessary to keep their heads above the 
water.  
 
Light and Dark test (DLT) was performed in a quiet, darkened room. Mice were 
transported a short distance from the holding facility to the testing room in their home 
cages. Mice were next individually housed in cages containing a handful of bedding from 
their home cage and acclimated to the room at least 30 min before the test. The lit 
compartment was brightly illuminated with an 8 W fluorescent tube (400 lx). Naïve mice 
were placed individually in the testing chamber in the middle of the dark area facing 
away from the doorway to the light compartment. The test lasted 5 min, the number of 
entries and the time spent in the lit compartment were recorded. 
 
Morris water maze test (MWMT), Animals are transported to the testing room in 
their home cages, and left undisturbed for at least 30 minutes prior to the first trial. The 
maze is comprised of a large swimming pool (150cm diameter) filled with water (23 C) 
made opaque with non-toxic white paint. The pool is located in a brightly lit room filled 
with visual cues, including geometric figures on the walls of the maze demarking the four 
	  
	   107	  
fixed starting positions of the trials, at (12:00, 3:00, 6:00 and 9:00). A 15 cm round 
platform is hidden 1 cm beneath the surface of the water at a fixed position. Each daily 
trial block consisted of four swimming trials, with each mouse starting from the same 
randomly chosen starting position. The starting position is varied between days. On day 
1, mice that fail to find the platform within 2 min are guided to the platform. They must 
remain on the platform for 15 s before they are returned to their home cage. Mice are not 
guided to the platform after day 1, and the time it takes them to reach the platform over 
repeated trials (3 trails/day for the next 10 days) is recorded as a measure of spatial 
learning. 
 
Novel Object Recognition (NOR)  
 
For Chapter 2 Part I, we used a modified version of the NOR task described by 
(Ennaceur and Delacour, 1988). The testing room was lit with two 60-W light bulbs and 
behavior sessions were recorded with a camera above the testing arena. The testing arena 
was a white, plastic transport box (55 X 40 X 15cm2) and was divided into two equal 
halves so that two sessions could occur simultaneously. Mice could not contact or see one 
another during the exposures. The light intensity was equal in all parts of the arena 
(around 20 lx). We used three different objects; each object was available in triplicate. 
The objects were (1) a blue, ceramic shoe (diameter 9.5cm, maximal height 6cm); (2) a 
black, plastic (8 X 3 X 9.5cm3); and (3) a clear plastic funnel (diameter 8.5 cm, maximal 
height 8.5 cm). The objects elicited equal levels of exploration as determined in pilot 
experiments. 
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Mice were transported to the testing room in the transport boxes filled with 
wooden bedding. The NOR paradigm was administered as previously described (Denny 
et al., 2012) with the exception that the NOR paradigm consisted of two 5-min exposures 
with a 3-min interexposure interval. Between exposures, mice were held individually in 
standard cages, the objects and arenas were cleaned using PDI sani-cloth HB germicidal 
Disposable Wipes (Orangeburg, NY), and the bedding was replaced. In general, the effect 
of context was analyzed using an ANOVA, using repeated measures where appropriate. 
Significant ANOVAs were follwed up with Fisher’s PLSD tests where appropriate. All 
main effects and interactions are noted in the text. All data were analyzed using StatView 
5.0 software (SAS Institute, Cary, NC). Alpha was set to 0.05 for all analyses. Data are 
expressed as means + SEM. * p < 0.05, ** p < 0.01, *** p < 0.001. 
For Part II, the NOR paradigm was conducted as previously described (Broadbent 
et al., 2010), in an opaque plastic box using 2 different objects: (1) a clear plastic funnel 
(diameter 8.5 cm, maximal height 8.5 cm) and (2) a black plastic box (9.5 cm3). These 
objects elicit equal levels of exploration as determined in pilot experiments (Denny et al., 
2012; Oury et al., 2013b). The NOR paradigm consists of 3 exposures over the course of 
3 days. On day 1, the habituation phase, mice are given 5 minutes to explore the empty 
arena, without any objects. On day 2, the familiarization phase, mice are given 10 
minutes to explore 2 identical objects, placed at opposite ends of the box. On day 3, the 
test phase, mice are given 15 minutes to explore 2 objects, one novel object and a copy of 
the object from the familiarization phase. The object that serves as the novel object 
(either the funnel or the box) as well as the left/right starting position of the objects are 
counterbalanced within each group. Mice are placed in the center of the arena at the start 
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of each exposure. Between exposures, mice are held individually in standard cages, the 
objects and arenas cleaned, and the bedding replaced. Preference for the novel object is 
assessed based on the fraction of time that a mouse spends exploring the novel object 
compared to the familiar object. Exploration is scored from video recordings of each 
exposure and recorded using the Stopwatch program. An equal exploration time for the 
two objects, or a decreased percentage of time spent with the novel object compared to 
WT controls indicates impairment in hippocampal memory. 
 
 
Contextual Fear Conditioning (CFC)  
 
For Chapter 2 Part I, the 3-shock CFC procedure was based on those of (Denny et 
al., 2012; Drew et al., 2010; Wiltgen et al., 2006). For the 3-shock CFC training 
procedure, mice were placed in the conditioning chamber, received 3 shocks at 180 s, 240 
s, and 300 s later (2 s, 0.75 mA), and were removed 15 s following the last shock. For 
context exposure, mice were placed in to the chamber for 300 s. All data is shown as an 
average of the percentage of freezing across the 300 s exposures.  
For context A exposures, the chambers had clear plastic front and back walls, 
stainless steel walls on each side, and stainless steel bars on the floor.  A house light was 
mounted directly above the chamber.  Each chamber was located inside a larger, 
insulated, plastic cabinet that provided protection from outside light and noise.  Each 
cabinet contained a ventilation fan that was operated during the sessions. A paper towel 
dabbed with lemon solution was placed under the stainless steel bars. Between runs, the 
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context was cleaned using PDI Sani-Cloth® HB Germicidal Disposable Wipes 
(Orangeburg, NY). 
Context A’ was a modified context A. For context A’ exposures, the stainless 
steel bars were covered with a white plastic insert and there was no scent associated with 
the chamber.  
Context B was also a modified context A. For context B exposures, the stainless 
steel bars were covered with a white plastic insert, the walls of the chambers were 
covered with colored plastic inserts so as to change the shape of the chamber, and the 
chamber was then filled with bedding.  The chamber was scented with anise, and the 
mice were transported to the apparatus in a white bucket.  
Significant ANOVAs were follwed up with Fisher’s PLSD tests where 
appropriate. All main effects and interactions are noted in the text. All data were analyzed 
using StatView 5.0 software (SAS Institute, Cary, NC). Alpha was set to 0.05 for all 
analyses. Data are expressed as means + SEM. * p < 0.05, ** p < 0.01, *** p < 0.001. 
For Part II, the conditioning apparatus consisted of sound attenuating conditioning 
boxes (Bioseb, France or MedAssociates, USA), and mice were run individually in the 
conditioning boxes.  The floor of the chamber consisted of stainless steel bars wired to a 
shock generator with scrambler for the delivery of foot shock. Signal generated by mouse 
movement was recorded and analyzed by a high sensitivity weight transducer system or 
by videotracking analyzed by Freezeframe software. The fear conditioning procedure 
took place over two consecutive days. On day 1, mice were placed in the conditioning 
chamber, received 3 foot-shocks (1 or 2 sec, 0.5 mA) which were administered at time 
points of 60, 120 and 180 sec after the animals were placed in the chamber. They were 
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returned to their home cage 60 sec after the final shock. Contextual fear memory was 
assessed 24 hr after conditioning by returning the mice to the conditioning chamber and 
measuring freezing behavior during a 4 min retention test. Freezing was scored and 
analyzed automatically using Packwin software (Bioseb, France) or Freezeframe software 
(Coulbourn Instruments). Freezing behavior was considered to occur if the animal freeze 
for at least a period of two seconds. 
 
The corneal ERG (electroretinogram): elicited by a strobe flash from dark-adapted 
mice was recorded using a saline wick electrode according to (Kong and Gouras, 2003). 
ERGs of normal configuration and A-wave peak to B-wave peak amplitudes in 
microvolts (uV) were recorded from both eyes simultaneously. The amplitudes and forms 
of the waves of the mutant mice were essentially identical to those of matched wild type 
strain, and the responses of all four mice were within normal limits (500-600 uV).  
 
Cell biology 
For primary culture of hindbrain neurons, E14.5 129 sv/ev WTembryos were used. 
Hindbrains were dissected out and collected in ice-cold filter sterilized HBSS buffered 
with 10mM HEPES until dissection was complete, at which point they were finely 
chopped into 2mm cubes, dissociated by trituration with a fire-polished Pasteur pipette 
and spun down at 4° C.  Cells were then plated onto poly-D-lysine coated coverslips or 
dishes in Neurobasal medium supplemented with 2% B27, 0.25mM Glutamax, 0.25 mM 
L-glutamine, penicillin G (50 U/ml), and streptomycin sulfate (50 mg/ml). Cultures were 
fed every 3-6 days with medium without L-glutamine.  
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For calcium imaging, primary hindbrain neurons seeded on 12mm coverslips 
were allowed to form structural networks. Cultures were washed with HBSS and loaded 
with 2.5 uM FURA-2, AM calcium indicator for 45 minutes at room temperature, 
according to manufacturer protocol. Cells were then washed to remove excess indicator 
and incubated for 30 minutes to allow internalized esters to become de-esterified. 
30ng/ml of osteocalcin was prepared with the control buffer of 1x HBSS supplemented 
with 10mM HEPES buffer and 2mM CaCl2. Coverslips were perfused with control and 
osteocalcin and imaged using a Zeiss Observer Z1 microscope. As a final stimulation, 
cells were depolarized with 50mM KCl to determine the percentage of live cells being 
imaged. All treatments were recorded using Prairie View software (Prairie Technologies) 
and analyzed by Z axis profile plotting using ImageJ. 
 
Real-Time RNA transcript determination 
All dissections were performed in ice-cold PBS 1X under a Leica MZ8 dissecting light 
microscope. All parts of the brain isolated were snap frozen in liquid nitrogen and kept at 
-80ºC until use.  
RNA was isolated from brain tissue using TRIZOL (Invitrogen). cDNA synthesis was 
performed following standard protocol, q-PCR analyses were done using specific 
quantitative PCR primers (sequences available upon request), and expressed relative to 
Gapdh levels. 
 
Ex vivo dual perfusion 
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Maternal-fetal transport of osteocalcin was monitored using ex vivo dual perfusion 
of the mouse placenta (Goeden and Bonnin, 2013). Osteocalcin (300 ng/ml) was injected 
on the maternal side through the uterine artery in placentas obtained from WT mice at 
E14.5, E15.5, and E18.5 of pregnancy (n=3 independent perfusion per age).  Osteocalcin 
transport through the placenta was analyzed by measuring the concentration of 
osteocalcin present in fetal eluates obtained through the umbilical vein, each time points 
(1-9) corresponding to a 10 minute collection period (at 5 ml/min). Collection time points 
(from 10 to 30 min of perfusion) were obtained during maternal fluid infusion; time 
points 4-6 (from 30 to 60 min of perfusion) were obtained during osteocalcin infusion 
into the maternal uterine artery, whereas time points 7-9 (from 60 to 90 min of perfusion 





All dissections were performed in ice-cold PBS 1X under a Leica MZ8 dissecting 
light microscope. Brainstems were isolated from the cerebellum and the hypothalamus 
removed from the midbrain during collection. All parts of the brain isolated were snap 
frozen in liquid nitrogen and kept at -80°C until use.  
Immunofluorescence of adult and embryonic brains was performed on 20mm 
coronal cryostat slices of tissue fixed with 4% PFA, embedded in cryomatrix (Tissue-
Tek) and stored at -80°C. Sections were allowed to dry at room temperature, post-fixed in 
4% PFA followed by permeabilization with 0.1% Triton detergent. After room 
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temperature blocking with donkey serum, sections were incubated with anti-NeuN 
antibody (Millipore) overnight at 4°C. Slides were mounted with Fluorogel (Electron 
Microscopy Sciences). The dentate gyrus area were quantifying using ImageJ program on 
8 serial sections (30mm) for each mice. 
For In situ mRNA hybridization, 20uM coronal and sagittal sections of adult 
mouse bone and brain were cryostat sectioned and collected on positively charged 
microscope slides. Cryostat sections were incubated with a DIG-labeled probe at 69° C 
followed by incubation with alkaline phosphatase-conjugated anti-DIG antibody, and 
developed by incubation with NBT/BCIP. 
Cresyl violet staining to visualize brain morphology was carried out by incubating 
20mm cryosections defatted with 1:1 chloroform:ethanol in cresyl violet acetate (1g/L) 
overnight. The stain was differentiated using ethanol and xylene and mounted using DPX 
mounting medium for histology (Sigma). The lateral ventricle area versus brain area was 
quantified using ImageJ program on 8 serial sections (20mm) for each mice. 
To assess apoptosis in WT and Osteocalcin-/- brains, 20mm cryostat sections were 
processed using the ApopTag® Fluorescein Direct In Situ Apoptosis Detection Kit 
(Millipore) according to manufacturer’s protocol.  Images were obtained using Leica DM 
4000B, and Image J was used to quantify cell number and intensity of staining. The 
number of apoptotic cells was quantified using ImageJ program on 10 serial sections 
(20mm) for each mice. 
Doublecortin (DCX) immunohistochemistry was performed as previously described 
(Denny et al., 2011). BrdU immunohistochemistry was performed as previously 
described (Denny et al., 2011).  
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Binding Assays  
Brains from 8-week-old mice were snap-frozen in isopentane, 20mm thick 
sections prepared and desiccated overnight at 4°C under vacuum. The following day, 
sections were rehydrated in ice cold binding buffer (50 mM Tris-HCl, pH 7.4, 10mM 
MgCl2, 0.1mM EDTA and 0.1% BSA) for 15 min and incubated for 1hr in the presence 
of biotinylated osteocalcin (300ng/ml) or biotynylated recombinant GST as a control (1.5 
mg/ml). After washing in harvesting buffer (50 mM Tris-HCl, pH 7.4), samples were 
fixed in 4% paraformaldehyde for 15 min, washed in PBS and incubated with goat anti-
biotin antibody (1:1000, Vector laboratories) over night at 4 oC. Signal was visualized by 
incubating anti-goat IgG Cy-3 using Leica DM 5000B microscope (Leica). The binding 
assays were perform on adjacent sections for each conditions tested. 
 
Biochemistry and Molecular Biology 
For Western blotting, frozen hippocampi from E18.5 embryos were lysed and 
homogenized in 250ml tissue lysis buffer (25mM Tris HCl 7.5; 100mM NaF; 10mM 
Na4P2O7; 10mmM EDTA; 1% NP 40).  Samples were pooled together in threes by 
genotype to reduce variability. Proteins were transferred to nitrocellulose membranes, 
and blocked with TBST-5%milk prior to overnight incubation with primary antibody in 
TBST-5%BSA. HRP-coupled secondary antibodies and ECL were used to visualize the 
signal. 
 
High performance liquid chromatography 
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Serotonin, catecholamine, and GABA contents were measured by HPLC (Bach et al., 
2011). Neurotransmitter contents in 7 to 15 mice of each genotype were measured in 
cerebral cortex, striatum, hippocampus, hypothalamus, midbrain, brainstem and 
cerebellum. 
 
Brain Explants  
Brains were dissected and incubated for 30 minutes in ice-cold oxygenated 
artificial cerebrospinal fluid (ACSF). Brains were then sliced at 500um at the midbrain, -
1.55 to -2.35mm from the bregma, and at the level of the brainstem, from -4.04 to -
4.48mm and from -4.60 to -5.20mm from the bregma, to include the median and dorsal 
raphe, respectively. These slices were incubated in artificial cerebro-spinal fluid (ACSF) 
constantly oxygenated (95% O2 and 5% CO2) for 4 h, after which they were treated with 
either osteocalcin (10ng/ml) or PBS for four hours. Expression of Tph2, TH, GAD1, 
GAD2 was measured by QPCR relative to Gapdh levels.  
 
Ex vivo dual perfusion 
Maternal-fetal transport of osteocalcin was monitored using ex vivo dual perfusion 
of the mouse placenta (Goeden and Bonnin, 2013). Osteocalcin (300ng/ml) was injected 
on the maternal side through the uterine artery in placentas obtained from WT mice at 
E14.5, E15.5, and E18.5 of pregnancy (n=3 independent perfusion per age).  Osteocalcin 
transport through the placenta was analyzed by measuring the concentration of 
osteocalcin present in fetal eluates obtained through the umbilical vein, each time points 
(1-9) corresponding to a 10 minute collection period (at 5 ul/min). Collection time points 
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(from 10 to 30 min of perfusion) were obtained during materal fluid infusion; time points 
4-6 (from 30 to 60 min of perfusion) were obtained during osteocalcin infusion into the 
maternal uterine artery, whereas time points 7-9 (from 60 to 90 min of perfusion resp.), 
the maternal uterine artery was infused with maternal fluid alone. 
 
Physiological Measurements  
Physical activity, including ambulatory activity (xamb) and total activity (xtot) 
was measured using infrared beams connected to the Oxymax system as previously 
described (Yadav et al., 2009). Energy expenditure measurements were obtained using a 
six-chamber oxymax system (Columbus Instruments, Ohio). After 30 hr acclimatation to 
the apparatus, data for 24 hr measurement were collected and analyzed as recommended 
by the manufacturer. Oxygen consumption was calculated by taking the difference 
between input oxygen flow and output oxygen flow. Carbon dioxide production was 
calculated by taking the difference between output and input carbon dioxide flows. The 
respiratory exchange ratio (RER) corresponded to the ratio between carbon dioxide 
production and oxygen consumption (RER= VCO2/VO2). Heat production was 
calculated by indirect calorimetry using the flowing formulas: 
Heat = CV X VO2/BW 
CV= 3.815+1.232 X RER 
 
Hormonal measurement 
Osteocalcin and leptin contents in serum (ng/ml) and tissues (ng/mg) were measured with 
specific ELISAs (Mouse osteocalcin EIA kit (BT-470 Biomedical Technologies Inc. and 
	  
	   118	  
EZML-82K, Millipore). CTX content in serum (ng/ml) were measured with specific 
ELISAs (RatLaps™ (CTX-I) EIA (Immunodiagnosticsystems). Circulating levels of the 
carboxylated, undercarboxylated or uncarboxylated forms of osteocalcin were measured 
by ELISA (Ferron et al., 2010). 
 
Electrophysiology  
Brain slice preparation and electrophysiological recordings were performed as 
reported previously (Rao et al., 2007). Briefly, WT mice were anesthetized with ether and 
then decapitated. The brains were rapidly removed and immersed in an oxygenated bath 
solution at 40C containing (in mM): sucrose 220, KCl 2.5, CaCl2 1, MgCl2 6, NaH2PO4 
1.25, NaHCO3 26, and glucose 10 pH 7.3 with NaOH. Coronal slices (350 µm thick) 
containing dorsal raphe (DR) or locus coeruleus were cut on a vibratome and maintained 
in a holding chamber with artificial cerebrospinal fluid (ACSF) (bubbled with 5% CO2 
and 95% O2) containing (in mM): NaCl 124, KCl 3, CaCl2 2, MgCl2 2, NaH2PO4 1.23, 
NaHCO3 26, glucose10, pH 7.4 with NaOH, and were transferred to a recording chamber 
constantly perfused with bath solution (33°C) at 2 ml/min after at least a 1 hr recovery. 
Whole-cell current clamp was performed to observe action potentials in DR neurons with 
a Multiclamp 700A amplifier (Axon instrument, CA). The patch pipettes with a tip 
resistance of 4-6.  
MΩ were made of borosilicate glass (World Precision Instruments) with a Sutter 
pipette puller (P-97) and filled with a pipette solution containing (in mM): K-gluconate 
(or Cs-gluconate) 135, MgCl2 2, HEPES 10, EGTA 1.1, Mg-ATP 2, Na2-
phosphocreatine 10, and Na2-GTP 0.3, pH 7.3 with KOH. After a giga-Ohm (GΩ) seal 
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and whole-cell access were achieved, the series resistance (between 20 and 40 MΩ) was 
partially compensated by the amplifier. The GABAergic neurons were identified using a 
Gad67-Egfp Knock in mice (Tanaka et al., 2006). The noradrenergic neurons of the locus 
coeruleus were identified by standard criteria, which included spontaneous activity 
displaying a regular rhythm and firing rate between 0.5 and 5 Hz, characteristic spikes 
with a long-lasting (>2 ms), positive–negative waveform action potentials and the 
biphasic excitation–inhibition response to pressure applied on contralateral hind paw 
(paw pinch), as previously described in mice and rats (Cedarbaum and Aghajanian, 1976; 
Gobbi et al., 2007). 5-HT neurons were identified according to their unique properties 
(longduration action potential, activation by norepinephrine and inhibition by serotonin 
itself) reported previously (Liu et al., 2002). Under current clamp, 5-HT neurons were 
usually quiescent in slices because of the loss of noradrenergic inputs. The application of 
α1-adrenergic agonist phenylephrine (PE, 3 µM) elicited action potentials and the 
application of serotonin creatinine sulfate complex (3 µM) inhibited action potentials in 
these neurons. The effect of osteocalcin on 5-HT neurons was examined in DR neurons 
responding to both PE and serotonin. Before the application of osteocalcin, action 
potentials in brainstem neurons were restored by application of PE in the bath (Liu et al., 
2002). All data were sampled at 3-10 kHz and filtered at 1-3 kHz with an Apple 
Macintosh computer using Axograph 4.9 (Axon Instruments). Electrophysiological data 
were analyzed with Axograph 4.9 and plotted with Igor Pro software (WaveMetrics, Lake 
Oswego, OR). 
 
Protein expression and purification: 
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The complete amino acid sequence of mouse osteocalcin used in this study is: 
YLGASVPSPDPLEPTREQCELNPACDELSDQYGLKTAYKRIYGITI (E: glutamic 
acids that are gamma-glutamyl carboxylated in vivo; C: the two cysteines that form a 
disulfide bond). 
The coding sequence for amino acids Tyr50 - Ile95 of murine OCN (GeneBank 
accession: NM_007541) was synthesized using codon optimisation for E.coli (Geneart, 
Regensburg, Germany) and cloned in a modified version of pET28a (Novagen, Merck, 
Darmstadt, Germany). The expressed protein consists of eight N-terminal consecutive 
histidine residues followed by a linker sequence and a tobacco etch virus (Tev)-protease 
cleavage site (ENLYFQG). This construct was transformed into E.coli BL21Star(DE3) 
(Invitrogen, Carlsbad, CA, USA). Expression was done using an autoinducing medium 
(1) allowing the cells to grow for 18 hours at 30°C. Cells were harvested by 
centrifugation and resuspended in 500 mM NaCl, 50 mM Tris, pH 8.0, supplemented 
with 2U/mL Benzonase (Merck, Darmstadt, Germany) and complete EDTA-free protease 
inhibitor tablets (Roche Diagnostics, Mannheim, Germany). The resuspended cells were 
lysed with the aid of a high pressure homogenizer (NS1001C Panda2K model, GEA Niro 
Soave, Parma, Italy). After disruption, the lysate was centrifuged for 60 min at 13.700 g 
and 4°C. Capture was done using a Ni-Sepharose 6 FF column (GE Healthcare, Freiburg, 
Germany) equilibrated with 500 mM NaCl, 50 mM Tris, pH 8.0. Protein was eluted from 
the column by applying a linear gradient to 500 mM imidazol in the same buffer. 
Corresponding fractions were pooled and digested with Tev-protease at 4°C over night in 
150 mM NaCl, 50 mM Tris, pH 8.0, 1 mM DTT. The digest was passed a second time 
over the Ni-Sepharose 6 FF column and the flowthrough, containing the cleaved protein, 
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was collected. Further purification was done by gelfiltration chromatography on a 
Superdex 30 pg column (GE Healthcare) using phosphate buffered saline (PBS, Gibco, 
Invitrogen) as running buffer. All chromatographic steps were done on an ÄKTA 
chromatography system (GE Healthcare). For further endotoxin removal, the protein 
solution was passed over an Acrodisc syringe filter (Pall, Dreieich, Germany). After 
concentration (Amicon centrifugal filter units, 3 kDa cut off, MerckMillipore, Darmstadt, 
Germany) to a concentration of 5,6 mg / mL (as determined by absorption at 280 nm), the 
protein solution was sterile filtered (Millex GV syringe filter unit, MerckMillipore, 
Darmstadt, germany), aliquoted and immediatly stored at -80°C until further usage. 
Endotoxin content was checked with the EndoSafe PTS system (Charles River 
Laboratories International, Charleston, SC, USA) and measured endotoxin-level was < 1 
EU/ml. As judged from a coomassie-stained SDS-PAGE, the protein is >95% pure (Fig. 
1). The integrity of the protein was checked and confirmed by N-terminal amino acid 
sequencing (Edman degradation) and intact MS-analysis. 
The coding sequence for amino acids Tyr50 - Ile95 of murine OCN (GeneBank 
accession: NM_007541) and its mutant form (E13Q) were cloned into the prSETA vector 
(Thermofisher). The expressed protein consists of 6 N-terminal consecutive histidine 
residues followed by an Xpress epitope and linker sequence. Bacteria were grown to an 
OD of 0.8, expression of recombinant protein was induced by adding 1mM of IPTG at 37 
C for 4 hours. Cells were collected and lysed in 50mM Tris pH 7.65, 10% glycerol, 1M 
NaCl, 0.01%NP40, 10,mM Imidazole. Capture was done using a Ni-NTA resin 
equilibrated in lysis buffer for 1 hr at 4 C. Purified proteins were washed in lysis buffer 
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and eluted for 30 minutes by adding 300mM Imidazole. Proteins were dialized in 1xPBS 




WT and Ocn-/- mice aged 12 weeks were housed individually on pine shavings in 
clear polycarbonate cages (32 × 14 × 13 cm) equipped with running wheels (13 cm 
diameter). Cages were placed in light-tight chambers with independent lighting control 
and ventilation (Phenome Technologies, Inc., Skokie, IL). Animals were provided 
with ad libitum access to food and water, and maintained in constant dim red light (peak 
wavelength 639 nm, half-maximal width 18 nm, Avago Techologies, San Jose, 
CA)(Butler and Silver, 2011). Illuminance was 0.3 lux at the cage floor (ILT1700, 
International Light Technologies, Peabody, MA, USA). All animal maintenance and 
experimental protocols were approved by Columbia University's Institutional Animal 
Care and Use Committee. 
 
Mass spectrometry analysis 
MATERIAL 
Dithiothreitol (DTT), acetonitrile (ACN), ammonium bicarbonate, trifluoretic 
acids (TFA), and iodoacetamide (IAA) were from Thermo Fisher Scientific (Waltham, 
MA). Trypsin Gold, mass spectrometry grade, was from Promega (Madison, WI). 
Nanopure water was prepared with use of Milli-Q water purification system (Millipore, 
Billerica, MA). 
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METHOD 
Tissue homogenization 
Tissue lysates were generated by homogenizing 50mg of hippocampal tissues in 
the lysis buffer (50mM Ammonium Bicarbonate, 4M Urea, and protease cocktail) using 
1.4mm ceramic beads and the Omni Bead Ruptor Homogenizer (Omni International, 
GA). Protein concentration in total lysate was determined by the EZQ Protein 
Quantification Assay (Life Technology Corp. CT).  
 
In Solution Protein Digestion  
5µg of proteins were reduced, alkylated, and digested in 50 µL of 125 ng Trypsin 
Gold reconstituted in 50 mM ammonium bicarbonate at 37°C overnight. After the 
digestion was complete, the peptide mix was centrifuged subsequently for 30 minutes at 




The concentrated peptide mix was reconstituted in a solution of 2 % acetonitrile 
(ACN), 2 % formic acid (FA) for MS analysis. Peptides were eluted from the column 
using a Dionex Ultimate 3000 Nano LC system with a 10 min gradient from 2% buffer B 
to 35 % buffer B (100 % acetonitrile, 0.1 % formic acid). The gradient was switched 
from 35 % to 85 % buffer B over 1 min and held constant for 2 min. Finally, the gradient 
was changed from 85 % buffer B to 98 % buffer A (100% water, 0.1% formic acid) over 
1 min, and then held constant at 98 % buffer A for 5 more minutes. The application of a 
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2.0 kV distal voltage electrosprayed the eluting peptides directly into the Thermo Fusion 
Tribrid mass spectrometer equipped with an EASY-Spray source (Thermo Scientific). 
Mass spectrometer-scanning functions and HPLC gradients were controlled by the 
Xcalibur data system (Thermo Finnigan, San Jose, CA). 
 
Database Search and Interpretation of MS/MS Data 
Tandem mass spectra from raw files were searched against a Drosophila protein 
database using the Proteome Discoverer 1.4 software (Thermo Finnigan, San Jose, CA). 
The Proteome Discoverer application extracts relevant MS/MS spectra from the .raw file 
and determines the precursor charge state and the quality of the fragmentation spectrum. 
The Proteome Discoverer probability-based scoring system rates the relevance of the best 
matches found by the SEQUEST algorithm. The mouse protein database was downloaded 
as FASTA-formatted sequences from Uniprot protein database (database released in 
May, 2015). The peptide mass search tolerance was set to 10ppm. A minimum sequence 
length of 7 amino acids residues was required. Only fully tryptic peptides were 
considered. To calculate confidence levels and false positive rates (FDR), Proteome 
Discoverer generates a decoy database containing reverse sequences of the non-decoy 
protein database and performs the search against this concatenated database (non-decoy + 
decoy). At least 2 PSMs were required for positive identification and the discriminant 
score was set at less than 5% FDR determined based on the number of accepted decoy 
database peptides to generate protein lists for this study. Spectral counts were used for 
estimation of relative protein abundance between samples. 
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Plasma collection 
Pooled mouse plasma was collected from young (3 months) WT or Ocn-/- or aged 
(16 months) mice by intracardial bleed at time of euthanasia. Plasma was prepared from 
blood collected with EDTA into Capiject T-MQK tubes followed by centrifugation at 
1,000g for 10 minutes. All plasma aliquots were stored at −80 °C until use. Before 
administration, plasma was dialyzed using 3.5-kDa D-tube dialyzers (EMD Millipore) in 
PBS to remove EDTA. Young adult mice were systemically treated with plasma (100 µl 
per injection) by injections into the tail vein eight times over 24 days. 
RNASeq 
RNA was extracted from cells using the RNeasy Micro Kit (QIAGEN) and the quality of 
purified RNA samples was determined using a Bioanalyzer 2100 (Agilent) with an RNA 
Pico kit. Extracted RNA samples were amplified by Ovation® RNA-Seq System V2 
(NuGEN) Kit. Amplified cDNA was labeled with Encore biotin module Kit (NuGEN) for 
RNASeq applications Illumina Truseq RNA Sample Prep v2 using the LT protocol. RNA 
was sequenced at 30M paired 100 bp reads reads per sample on an Illumina 2500 HISeq 
instrument.   
Bases were called with Illumina’s Real Time Analysis (RTA 1.9) (Illumina, 
2015b). Adaptors were trimmed and reads were converted from BCL to Fasta format with 
bcl2fastq 1.8.4 (Illumina, 2015a). Reads were mapped to the mm9 mouse genome with 
Bowtie2 (Langmead and Salzberg, 2012) 2.0.0-beta7 and TopHat2 (Kim et al., 2013) 
2.0.4. Reads were counted with HTSeq-0.6.1p2 (Anders et al., 2015). 
In situ hybridization 
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For in situ hybridization, tissues were fixed in 4% paraformaldehyde/PBS 
overnight at 4°C and then embedded in paraffin after dehydration and sectioned at 5 µm. 
In situ hybridization was performed using 35S-labeled riboprobe as previously described 
(Ducy et al., 1997). The Gpr158 probe is a 1kb fragment of the Gpr158 3′ UTR. 
Hybridizations were performed overnight at 58°C, and washes were performed at 63°C. 
 
Tango assay 
HTLA cells are transfected with GPCR tango constructs overnight. The next day 
cells were plated in 384-well plates and incubated for at least 6 hours to recover prior to 
osteocalcin stimulation. Cells were incubated overnight with Osteocalcin (3ng/ml). The 
following day, medium is removed and 20 µl per well of BrightGlo reagent was added. 
The plate was incubated for 20 minutes at room temperature in the dark before being 
counted on a luminescence counter. 
Statistical Analysis 
All data are presented as mean ± s.e.m. Unless otherwise noted, statistical analyses were 
performed using unpaired, two-tailed Student’s t-test for comparison between two groups 
and ANOVA test for experiments involving more than two groups. For all experiments, 
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